



## Impaired autophagy in the lower airways and lung parenchyma in stable COPD

Journal:	<i>ERJ Open Research</i>
Manuscript ID	ERJOR-00423-2023.R2
Manuscript Type:	Original Research Article
Date Submitted by the Author:	19-Sep-2023
Complete List of Authors:	<p>Levra, Stefano; University of Turin, Department of Clinical and Biological Sciences</p> <p>Rosani, Umberto; University of Padua, Department of Biology</p> <p>Gnemmi, Isabella; Fondazione Salvatore Maugeri, IRCCS, Laboratorio di Citoimmunopatologia apparato Cardio Respiratorio e Divisione di Pneumologia</p> <p>Brun, Paola; Università di Padova, Department of Molecular Medicine, unit of Histology</p> <p>Leonardi, Andrea; University of Padua, Department of Neuroscience, Ophthalmology Unit</p> <p>Carriero, Vitina; Università degli Studi di Torino, Department of Clinical and Biological Sciences</p> <p>Bertolini, Francesca ; Università degli Studi di Torino, Department of Clinical and Biological Sciences</p> <p>Balbi, Bruno; Mondo Medico</p> <p>Profita, Mirella; Institute of Translational Pharmacology, National Research Council</p> <p>Ricciardolo, Fabio Luigi Massimo; University of Turin, Clinical and Biological Sciences</p> <p>Di Stefano, Antonino; Istituti Clinici Maugeri SpA Società Benefit, Divisione di Pneumologia e Laboratorio di Citoimmunopatologia dell'Apparato Cardio Respiratorio</p>
Key Words:	COPD, autophagic stimulus, autophagy impairment, smoke, rehabilitation, Inflammation
Abstract:	<p>Background. There is increasing evidence of autophagy activation in COPD, but its role is complex and probably regulated through cell type-specific mechanisms. This study aims to investigate the autophagic process at multiple levels within the respiratory system, using different methods to clarify conflicting results reported so far.</p> <p>Methods. This cross-sectional study was performed on bronchial biopsies and peripheral lung samples obtained from COPD patients (30 and 12 per sample type, respectively) and healthy controls (25 and 22 per sample type, respectively), divided by smoking history. Subjects were matched for age and smoking history. We analysed some of the most important proteins involved in autophagosome formation, such as LC3 and p62, as well as some molecules essential for lysosome function, such as LAMP1. Immunohistochemistry was used to assess the autophagic</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	<p>process in both sample types. ELISA and transcriptomic analysis were performed on lung samples.</p> <p>Results. We found increased autophagic stimulus in smoking subjects, regardless of respiratory function. This was revealed by immunohistochemistry through a significant increase in LC3 (<math>p &lt; 0.01</math>) and LAMP1 (<math>p &lt; 0.01</math>) in small airway bronchiolar epithelium, alveolar septa, and alveolar macrophages. Similar results were obtained in bronchial biopsy epithelium by evaluating LC3B (<math>p &lt; 0.05</math>), also increased in homogenate lung tissue using ELISA (<math>p &lt; 0.05</math>). Patients with COPD, unlike the others, showed an increase in p62 by ELISA (<math>p &lt; 0.05</math>). No differences were found in transcriptomics analysis.</p> <p>Conclusions. Different techniques, applied at post-transcriptional level, confirm that cigarette smoke stimulates autophagy at multiple levels inside the respiratory system, and that autophagy failure may characterise COPD.</p>





**IRCCS Veruno**  
via per Revislate, 13 - 28010 Veruno (NO)  
tel. 0322 884711  
e-mail: veruno@icsmaugeri.it

To the Chief Editor  
Prof. Barreiro  
Hospital del Mar IMIM  
CIBERES Group and CEXS  
Pompeu Fabra University  
Barcelona, Spain

Dear Professor Barreiro,

Please find enclosed the manuscript entitled “**Impaired autophagy in the lower airways and lung parenchyma in stable COPD**”, which we would like to resubmit for publication after revision (R2) at ERJ Open Research. It appears that Reviewer 2 did not consider our responses to his comments. In any case, we added a new point-by-point response to his comments, with more explanations, and a revised version of the manuscript (R2) with adopted changes. The manuscript preparation guidelines were followed in the preparation of R2 text. All authors have read the R2 version of the manuscript and agree to its resubmission to the journal.

Looking forward to your response

Sincerely yours,

Di Stefano Antonino, PhD  
Divisione di Pneumologia e  
Laboratorio di Citoimmunopatologia  
Dell'Apparato Cardio Respiratorio  
Istituti Clinici Scientifici Maugeri, IRCCS  
Via per Revislate 13  
28013 Gattico-Veruno (NO)  
Tel: +39 0322 884963  
Email: antonino.distefano@icsmaugeri.it

## Point-by-point response

Date: September 19th, 2023

Manuscript ID: ERJOR-00423-2023

Type of manuscript: Article

Title: Impaired autophagy in the lower airways and lung parenchyma in stable COPD.

Name of the Corresponding Author: Antonino Di Stefano

Email Address of the Corresponding Author: antonino.distefano@icsmaugeri.it

### Reviewer 1

Comments to the Author

The authors have answered my questions taking into account the limitations of using archival material.

These have been added to the limitations of the revised version. I have no further questions.

**Reply: We thank the Reviewer.**

### Reviewer 2

Comments to the Author

Levra et al. have attempted to elucidate the participation of autophagic process during COPD pathogenesis at multiple levels by using human lung samples. RNA sequencing detected no clear difference in expression levels of transcripts of autophagic molecules between CNS, CS, and COPD, respectively. Immunohistochemical evaluation showed increased expression levels of autophagy-associated proteins in both control smokers and COPD. ELISA showed significant increase of p62 in COPD lungs tissue homogenates. Although this comprehensive evaluation of autophagic molecules can be potentially interesting for understanding the involvement of autophagy in COPD pathogenesis, the reviewer's enthusiasm was severely hampered due to the paucity of mechanistic insight and the preliminary nature of experimental results.

1. Immunohistochemical quantification in table 5 showed no difference between CS, and COPD, indicating that alteration of autophagic molecules is simply affected by smoking status but did not directly link to COPD pathogenesis. Are there any association between expression levels of autophagic molecules and smoking status or respiratory function?

**Reply: No difference between CS and COPD in autophagic molecules emerged by immunohistochemistry, by which we analysed bronchial epithelium, alveolar macrophages and alveolar septa separately. However, a difference emerged for p62 by ELISA test on lung tissue homogenate.**

**In our study, no significant association emerged between expression levels of autophagic molecules and smoking history (pack years) or respiratory function, neither in bronchial**

1  
2  
3 biopsies nor in peripheral lung. This result is at least in part in line with those previously  
4 reported. In particular, in the study of *Mercado et al.* (Mercado N, Colley T, Baker JR, *et al.*  
5 Bicaudal D1 impairs autophagosome maturation in chronic obstructive pulmonary disease.  
6 *FASEB BioAdvances* 2019; 1: 688–705) no correlation emerged between autophagic  
7 molecules and smoking history or respiratory function in smoking controls and patients with  
8 mild-moderate COPD. A correlation emerged only in patients with severe or very severe  
9 COPD, of whom we only had bronchial biopsies due to the process of samples collection. The  
10 following statement has been included in the text (line 229-230): “No significant association  
11 emerged between the expression levels of autophagic molecules in bronchial biopsies and  
12 smoking history or respiratory function”. A similar statement was added concerning  
13 peripheral airways (line 248-250).  
14  
15  
16

- 17  
18  
19  
20  
21  
22
2. In table 6, ELISA was performed for only limited autophagic molecules. Other molecules included in immunohistochemistry should be performed. Furthermore, to further clarify the clinical implication of p62, COPD cases should be divided based on the severity as demonstrated in table 4.

23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

Reply: In this study, lung parenchyma samples were obtained from patients undergoing resection surgery for a solitary peripheral neoplasm. Patients with severe or very severe COPD were not eligible for surgery, so lung samples were not available for useful comparison. We clarified this issue in the text (line 164-165).

ELISA tests were performed after immunohistochemistry, so we selected only autophagy molecules with significant differences between groups emerged from immunohistochemistry (added in the text, line 187-188). ELISA tests were performed for the most relevant molecules contributing to the autophagic flux in the lung parenchyma of CNS, CS and mild-moderate COPD patients. This experiment showed a clear increase of p62 in COPD patients compared to both CS and CNS (median values: 12.15 vs 0 vs 0 ng/ml, respectively for COPD, CS and CNS - Table 5). These findings, also confirmed by immunohistochemistry (particularly for alveolar macrophages - Table 4), clearly differentiate patients with COPD from control smokers. As stated in the manuscript, increased levels of autophagic molecules are frequently observed also in control smokers but impairment of autophagy (due to p62 increase) is only evident in COPD patients. As stated in the previous response, no significant associations emerged between the expression levels of autophagic molecules, included p62 protein, and smoking history or respiratory function.

- 43  
44  
45
3. Representative pictures of immunohistochemistry should be presented in all experiments.

46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Reply: In this study bronchial biopsies as well as peripheral lung specimens were used for immunohistochemistry, analysing LC3A, LC3B, cathepsin B, cathepsin D, beclin-1, p62, LAMP1 and TFEB. The immunostaining for all the antigens studied was scored in the intact bronchial epithelium, as well as in the lamina propria. All bronchioles, alveolar macrophages and alveolar septa observed in each lung section specimen were also analysed. In view of the number of immunostainings, in the first version of the manuscript we decided to show an image of p62, the molecule most representative of autophagy impairment, together with a double staining for LC3B, the autophagy marker most expressed in alveolar macrophages. Under request of the Reviewer, in the revised version of the manuscript we have added a new figure showing bronchiolar epithelium, alveolar macrophages and alveolar septa of control non-smokers and COPD patients immunostained for identification of LC3A and LAMP1, all molecules significantly changed in the peripheral airways of our study. We believe that images included in the revised version of the paper (Figures 2 and 3 of the revised manuscript) well support our data showed in results section and tables.

In any case, we are available to show photomicrographs of the other molecules (cathepsin B and D, beclin-1 and TFEB) in case of specific request by the Editor.

4. Although authors concluded that autophagy failure may be a potential factor leading the COPD development, the presented results did not sufficiently support this conclusion. Based on the presented results, the meaning of autophagy failure is not clear.

Reply: We respectfully disagree with the opinion of this Reviewer. In the present study, as well as in others previously published by other Authors (Fujii S, Hara H, Araya J, *et al.* Insufficient autophagy promotes bronchial epithelial cell senescence in chronic obstructive pulmonary disease. *Oncoimmunology* 2012; 1: 630–641. Tran I, Ji C, Ni I, *et al.* Role of cigarette smoke-induced aggresome formation in chronic obstructive pulmonary disease-emphysema pathogenesis. *Am. J. Respir. Cell Mol. Biol.* 2015; 53: 159–173. Vij N, Chandramani-Shivalingappa P, Van Westphal C, *et al.* Cigarette smoke-induced autophagy impairment accelerates lung aging, copd-emphysema exacerbations and pathogenesis. *Am. J. Physiol. - Cell Physiol.* 2018; 314: C73–C87), accumulation of p62 is considered a representative indicator of insufficient autophagic clearance and thus of autophagy failure. Our conclusions were based on the integration of our findings together with information obtained by the already published studies.

We have reported autophagy failure in peripheral lung of patients with mild-moderate COPD in alveolar macrophages (Table 4) and in protein lung extracts (Table 5) by using two different technical approaches, immunohistochemistry and ELISA tests, applied to the same lung specimens. In our opinion, these data are well presented and discussed in the revised (R2) manuscript. In the present study we privileged the immuno-histological analysis of the autophagic flux in COPD and control subjects. This approach is original and not frequently adopted by other Authors. For this reason it may contribute to a deeper evaluation of the autophagic flux and its impairment in the lungs of COPD patients.

In response to the Reviewer's comment, we modified the conclusions in both the abstract and the main text of the revised manuscript (lines 326-327).

Sincerely,

Dr. Antonino Di Stefano

# 1 2 1 **Impaired autophagy in the lower airways and lung parenchyma in stable COPD**

3  
4 2 Stefano Levra MD<sup>1</sup>, Umberto Rosani PhD<sup>2</sup>, Isabella Gnemmi<sup>3</sup>, Paola Brun PhD<sup>4</sup>, Andrea Leonardi  
5 3 MD<sup>5</sup>, Vitina Carriero PhD<sup>1</sup>, Francesca Bertolini PhD<sup>1</sup>, Bruno Balbi MD<sup>6</sup>, Mirella Profita PhD<sup>7</sup>,  
6 4 Fabio Luigi Massimo Ricciardolo MD<sup>1,7,8\*</sup>, Antonino Di Stefano PhD<sup>3\*</sup>.

7  
8  
9 5 <sup>1</sup>Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, Italy.

10 6 <sup>2</sup>Department of Biology, University of Padova, via U. Bassi 58/b, 35121 Padova. <sup>3</sup>Divisione di  
11 7 Pneumologia e Laboratorio di Citoimmunopatologia dell'Apparato Cardio Respiratorio, Istituti  
12 8 Clinici Scientifici Maugeri, IRCCS, Veruno, Novara, Italy. <sup>4</sup>Department of Molecular Medicine,  
13 9 Histology Unit, University of Padova, Padova, Italy. <sup>5</sup>Department of Neuroscience, Ophthalmology  
14 10 Unit, University of Padova, Padova, Italy. <sup>6</sup>Mondomedico, Borgomanero, Novara, Italy. <sup>7</sup>Institute  
15 11 of Translational Pharmacology, National Research Council (IFT-CNR), Section of Palermo,  
16 12 Palermo, Italy, <sup>8</sup>Severe Asthma and Rare Lung Disease Unit, San Luigi Gonzaga University  
17 13 Hospital, Orbassano, Turin, Italy

18  
19  
20  
21 14  
22  
23 15 \*These authors contributed equally to the present work

24 16  
25 17  
26 18 Correspondence to:

27 19  
28 20 Antonino Di Stefano, PhD  
29 21 Istituti Clinici Scientifici Maugeri, IRCCS  
30 22 Laboratorio di Citoimmunopatologia  
31 23 dell'Apparato Cardio Respiratorio  
32 24 Via per Revislate, 13  
33 25 28010 Veruno (NO), Italy  
34 26 Tel: +39 0322 884711  
35 27 Fax: +39 0322 884776  
36 28 E-mail: [antonino.distefano@icsmaugeri.it](mailto:antonino.distefano@icsmaugeri.it)

## 37 38 39 29 40 30 41 31 42 32 43 33 **Keywords**

44  
45 34 COPD, autophagic stimulus, autophagy impairment, smoke, rehabilitation, inflammation

## 46 47 35 48 49 36 **Abbreviations**

50  
51 37 BECN1, beclin-1

52  
53 38 CNS, control non-smokers

54  
55 39 COPD, chronic obstructive pulmonary disease

56  
57 40 CS, control smokers with normal lung function



1  
2 41 CTSB, cathepsin B  
3  
4 42 CTSD, cathepsin D  
5  
6 43 ELISA, enzyme-linked immunosorbent assay  
7  
8 44 FEV<sub>1</sub>, forced expiratory volume in one second  
9  
10 45 FVC, forced vital capacity  
11  
12 46 GOLD, Global Initiative for Chronic Obstructive Lung Disease  
13  
14 47 HBEC, human bronchial epithelial cell  
15  
16 48 LAMP1, lysosome-associated membrane protein 1  
17  
18 49 MAP1LC3 (LC3), microtubule-associated protein 1A/1B-light chain 3  
19  
20 50 MCOPD, mild/moderate chronic obstructive pulmonary disease  
21  
22 51 NUP62 (p62), nucleoporin 62  
23  
24 52 PI3K, phosphoinositide-3-kinase  
25  
26 53 SCOPD, severe/very severe chronic obstructive pulmonary disease  
27  
28 54 TFEB, transcription factor EB  
29  
30 55 VPS34, vacuolar protein sorting 34

31  
32  
33  
34 56  
35  
36 57 **Acknowledgements:** this work was supported, in part, by Istituti Clinici Scientifici Maugeri, SpA,  
37  
38 58 SB, IRCCS, Ricerca Corrente, and, in part, by Department of Clinical and Biological Sciences,  
39  
40 59 University of Turin, Orbassano, Turin, Italy.

41  
42  
43  
44 60 **Author contributions:** ADS, SL, UR and FLMR contributed in writing and revising the manuscript;  
45  
46 61 IG, VC, FB, MP and PB, contributed to the production of the data and accuracy of the data analysis;  
47  
48 62 AL and BB contributed to a critical revision of the manuscript.

49  
50  
51  
52 63 **Conflict of Interest:** All authors declare absence of any conflict of interest concerning this study

#### 53 64 **Ethics approval and consent to participate**

54  
55  
56  
57 65 This study was approved by the Istituti Clinici Scientifici Maugeri (protocol p112) and by Ethical  
58  
59 66 Committee of the San Luigi Gonzaga University Hospital (protocol n. 9544/2019) and performed  
60  
61 67 following the Declaration of Helsinki. Written informed consent was received from all patients  
62  
63 68 before inclusion in the study.



## Abstract

**Background.** There is increasing evidence of autophagy activation in COPD, but its role is complex and probably regulated through cell type-specific mechanisms. This study aims to investigate the autophagic process at multiple levels within the respiratory system, using different methods to clarify conflicting results reported so far.

**Methods.** This cross-sectional study was performed on bronchial biopsies and peripheral lung samples obtained from COPD patients (30 and 12 per sample type, respectively) and healthy controls (25 and 22 per sample type, respectively), divided by smoking history. Subjects were matched for age and smoking history. We analysed some of the most important proteins involved in autophagosome formation, such as LC3 and p62, as well as some molecules essential for lysosome function, such as LAMP1. Immunohistochemistry was used to assess the autophagic process in both sample types. ELISA and transcriptomic analysis were performed on lung samples.

**Results.** We found increased autophagic stimulus in smoking subjects, regardless of respiratory function. This was revealed by immunohistochemistry through a significant increase in LC3 ( $p < 0.01$ ) and LAMP1 ( $p < 0.01$ ) in small airway bronchiolar epithelium, alveolar septa, and alveolar macrophages. Similar results were obtained in bronchial biopsy epithelium by evaluating LC3B ( $p < 0.05$ ), also increased in homogenate lung tissue using ELISA ( $p < 0.05$ ). Patients with COPD, unlike the others, showed an increase in p62 by ELISA ( $p < 0.05$ ). No differences were found in transcriptomics analysis.

**Conclusions.** Different techniques, applied at post-transcriptional level, confirm that cigarette smoke stimulates autophagy at multiple levels inside the respiratory system, and that autophagy failure may ~~be a potential factor leading to COPD development~~ characterise COPD.

Word count: ~~220~~ 250

## 1. Introduction

1  
2 102 Autophagy is a pivotal process in cellular homeostasis, contributing to the regulation of intracellular  
3  
4 103 component processing and recycling [1]. There are several forms of autophagy, but three are  
5  
6 104 classically recognized: macroautophagy, microautophagy, and chaperone-mediated autophagy [1].  
7  
8  
9 105 Macroautophagy is the main form of autophagy and starts with the creation of transient double  
10  
11 106 membrane vesicles called autophagosomes. The process requires the formation of an isolated  
12  
13 107 membrane by a Class III phosphoinositide-3-kinase (PI3K) complex, which includes proteins such as  
14  
15  
16 108 Beclin-1 and vacuolar protein sorting 34 (VPS34) [2,3]. The PI3K complex also induces nuclear  
17  
18 109 localization of the transcription factor EB (TFEB), which activates several lysosomal and autophagy-  
19  
20 110 related genes [2]. The isolated membrane then elongates to form a double crescent-shaped membrane  
21  
22  
23 111 called the phagophore. Further elongation and closure of the phagophore to form the autophagosome  
24  
25 112 vesicle requires the presence of a protein called microtubule-associated protein 1A/1B-light chain 3  
26  
27 113 (MAP1LC3 or LC3) [4]. It is initially synthesized in a form called pro-LC3, which is converted to a  
28  
29  
30 114 proteolytically processed form called LC3A and finally modified through lipidation into LC3B [5].  
31  
32 115 Another protein deemed necessary to autophagosome formation and proper function is p62  
33  
34 116 (sequestosome-1, SQSTM1), which binds to LC3 and also to ubiquitinated proteins and organelles  
35  
36 117 designated for degradation [2,6]. Through this mechanism, the cargo is incorporated into the  
37  
38  
39 118 autophagosome vesicle for transport to the lysosome, resulting in the degradation of its contents by  
40  
41 119 lysosomal acid hydrolases. Several proteins essential for the proper functioning of the lysosome have  
42  
43 120 been identified, including cathepsins and the lysosome-associated membrane protein 1 (LAMP1),  
44  
45  
46 121 which is also required for the proper fusion of lysosomes with autophagosomes [7].  
47  
48 122 In the last years, evidence has emerged regarding autophagy activation in Chronic Obstructive  
49  
50 123 Pulmonary Disease (COPD) [2,8,9], a heterogeneous lung condition characterized by chronic  
51  
52  
53 124 respiratory symptoms and persistent airflow obstruction [10]. This activation is deemed to be mainly  
54  
55 125 due to cigarette smoking, as induced autophagy is considered fundamental in maintaining cellular  
56  
57 126 homeostasis in adverse environments. Indeed, it can preserve lung function through several  
58  
59  
60

1  
2 127 mechanisms, such as the inhibition of cellular senescence, the degradation of damaged organelles,  
3  
4 128 the suppression of myofibroblast differentiation, and the elimination of pathogens [11-15].  
5  
6 129 Nevertheless, autophagy is a highly dynamic process and if excessive can become harmful [13,16].  
7  
8  
9 130 Activated autophagy has been in fact linked to aberrant inflammatory response, mucus  
10  
11 131 hyperproduction, mucociliary clearance impairment, and cell death [17-21].  
12  
13 132 Data on autophagy based on human bronchial epithelial cells (HBECs) and lung tissues from COPD  
14  
15 patients are conflicting, and there is no unifying explanation for these discrepancies. The role of  
16 133 autophagy in COPD is considered complex and probably regulated via cell type specific mechanisms  
17  
18 134 [13,14,17,22,23]. Being both beneficial and harmful, autophagy can be considered as a double-edged  
19  
20 135 sword [24]. A prognostic role has also been attributed to autophagy in COPD patients and the use of  
21  
22 136 drugs able to modulate the process has been hypothesized [19,25,26]. However, a better  
23  
24 137 understanding of changes in the autophagic process in response to cigarette smoke is deemed  
25  
26 138 necessary before considering this process as a therapeutic target in COPD [16].  
27  
28 139 Considering the above, the purpose of this study is to investigate the autophagic process at different  
29  
30 140 levels within the respiratory system, comparing data obtained by multiple methods to achieve greater  
31  
32 141 robustness and try to better understand the conflicting results reported so far. A deeper knowledge of  
33  
34 142 the mechanisms of activation and dysregulation of autophagy in different areas of the respiratory  
35  
36 143 system and in different cell types could lead to the use of new specific drugs that can regulate the  
37  
38 144 autophagic process in a targeted manner to achieve optimal levels [2].  
39  
40  
41  
42  
43  
44  
45  
46  
47

## 48 147 **2. Methods**

### 49 50 148 *2.1 Subjects*

51  
52 149 Archival material from COPD patients and healthy controls was used in the present study [27]. All  
53  
54 150 subjects were recruited from the Respiratory Medicine Unit of the “Istituti Clinici Scientifici  
55  
56 151 Maugeri” (Veruno, Italy) and the Department of Clinical and Biological Sciences of the San Luigi  
57  
58  
59  
60

1  
2 152 Gonzaga University Hospital (Orbassano, Italy). The study complies with the Declaration of Helsinki  
3  
4 153 and has been approved by the Institutional Review Boards of Istituti Clinici Scientifici Maugeri  
5  
6 154 (protocol p112) and by Ethical Committee of the San Luigi Gonzaga University Hospital (protocol  
7  
8  
9 155 n. 9544/2019). All patients have signed an informed consent.  
10

### 11 156 *2.2 Lung function tests and volumes*

12  
13 157 Pulmonary function tests were performed in all subjects, according to current guidelines (see online  
14  
15  
16 158 supplement for details). The severity of the airflow obstruction in COPD patients was staged using  
17  
18 159 GOLD criteria [www.goldcopd.org].  
19

### 20 160 *2.3 Samples collection*

21  
22  
23 161 A fiberoptic bronchoscopy has been performed to collect bronchial biopsies from segmental and  
24  
25 162 subsegmental airways (4<sup>th</sup> to 6<sup>th</sup> airway generation) of 55 subjects, 30 of whom with COPD (see  
26  
27 163 online supplement for details). Thirty-four subjects undergoing lung resection surgery for a solitary  
28  
29  
30 164 peripheral neoplasm have been recruited, including 12 with COPD. All with mild or moderate disease  
31  
32 165 severity, according to the eligibility criteria for surgery. Specimens of their lung parenchyma were  
33  
34 166 frozen and used for analysis (see online supplement for details). All COPD patients were stable and  
35  
36 167 had not been treated with theophylline, antibiotics, antioxidants, mucolytics, and/or glucocorticoids  
37  
38  
39 168 in the month prior to bronchoscopy or surgery.  
40

### 41 169 *2.4 Immunohistochemistry in bronchial and peripheral lung tissue*

42  
43 170 Bronchial biopsies as well as peripheral lung specimens were used for immunohistochemical analysis.  
44  
45  
46 171 Sections from each sample were stained with antibodies specific for autophagy markers and proteins  
47  
48 172 (see online supplement for details). In particular for LC3A, LC3B, cathepsin B, cathepsin D, beclin-  
49  
50 173 1, p62, LAMP1 and TFEB. The immunostaining for all the antigens studied was scored in the intact  
51  
52  
53 174 bronchial epithelium, as well as in the lamina propria. All bronchioles, alveolar macrophages and  
54  
55 175 alveolar septa observed in each lung section specimen were also analysed (see online supplement for  
56  
57 176 details).  
58  
59  
60

## 2.5 RNA extraction, sequencing and analysis from bronchial and peripheral lung tissue

Frozen lung parenchymal tissues used for immunohistochemical analysis and bronchial rings from the same patients were also used for RNA extraction, sequencing and gene expression analysis (see online supplement for details). We considered the expression levels of MAP1LC3A, MAP1LC3B, CTSD, BECN1, NUP62, LAMP1 and TFEB genes. The expression level of these genes was also evaluated in <http://www.copdcellatlas.com/>, a COPD-dedicated gene expression browser of single-cell RNA sequencing data [28].

## 2.6 ELISA tests in peripheral lung specimens

LC3A, LC3B, LAMP1 and p62 proteins quantification was performed in the lung tissue homogenates obtained from frozen tissue specimens used also for immunohistochemical and RNA analysis (see online supplement for details). The choice of molecules analysed by ELISA was made on the basis of the differences revealed by immunohistochemistry.

## 2.7 Statistical analysis

Group data were expressed as mean (standard deviation) for functional data or median (range) or interquartile range (IQR) for morphologic data. Differences between groups were analysed using analysis of variance (ANOVA) for functional data. ANOVA was followed by an unpaired t-test for comparison between groups. The Kruskal Wallis test was applied to the morphologic data and followed, in case of a significant result, by a Mann-Whitney U-test for comparison between groups. Correlation coefficients were calculated using the Spearman rank method. Results were considered statistically significant for  $p < 0.05$ . Data analysis was performed using the Stat View SE Graphics program (Abacus Concepts Inc., Berkeley, CA-USA).

# 3. Results

## 3.1 Population of the study

1  
2 201 Bronchial biopsies were obtained from 30 COPD patients and 25 control subjects, 13 of whom had a  
3  
4 202 significant smoking history. The characteristics of all these subjects are reported in Table 1.  
5  
6 203 Peripheral lung samples were obtained from lung resections of 34 subjects, whose characteristics are  
7  
8  
9 204 shown in Table 2. Twelve of these had COPD, while the other 22 had normal lung function. Half of  
10  
11 205 the control subjects were smokers.  
12

### 13 206 *3.2 Gene expression level in bronchial rings and lung parenchyma*

15  
16 207 We examined RNA-seq expression data of 18 samples of bronchial rings and 23 lung parenchyma  
17  
18  
19 208 samples, which were obtained from frozen blocks adjacent to the specimens used for  
20  
21 209 immunohistochemical analysis and from frozen bronchial rings (Figure 1). Considering MAP1LC3A,  
22  
23 210 MAP1LC3B, CTSB, CTSD, BECN1, NUP62, LAMP1 and TFEB genes, no significant differences  
24  
25  
26 211 emerged in their expression levels between COPD, CS and CNS samples. CTSD resulted to be the  
27  
28 212 gene with the highest expression among the 8 selected ones in both tissues, with increasing expression  
29  
30 213 in CS and COPD compared to CNS. Similarly, CTSB also showed considerable expression levels in  
31  
32 214 both tissues, although the increasing trend is less evident. LAMP1 showed moderate expression levels  
33  
34  
35 215 in lung parenchyma only, whereas the expression of MAP1LC3A, MAP1LC3B, BECN1, NUP62,  
36  
37 216 and TFEB were lower. By browsing into single-cell RNA sequencing datasets, we confirmed the  
38  
39 217 high expression of CTSB in both COPD- and control-derived lung cells, whereas the other genes  
40  
41  
42 218 appeared less expressed (Supplementary Figure 1). Strikingly, CTSD resulted almost no expressed in  
43  
44 219 single-cell data.  
45  
46

### 47 220 *3.3 Immunohistochemistry of autophagic molecules in bronchial biopsies*

48  
49  
50 221 No differences in the expression of LAMP1, LC3A, p62, TFEB, Beclin-1 and cathepsin B/D were  
51  
52 222 found in the bronchial epithelium of COPD patients compared to CNS and CS, but some differences  
53  
54  
55 223 emerged for LC3B (Table 3). Specifically, the number of LC3B positive cells was significantly lower  
56  
57 224 in the bronchial epithelium of non-smokers than in CS ( $p=0.04$ ) and in patients with severe/very  
58  
59  
60

1  
2 225 severe COPD ( $p=0.01$ ). The level of LC3B positive cells in patients with severe/very severe COPD  
3  
4 226 was also significantly higher than in patients with mild/moderate disease ( $p=0.03$ ). The number of  
5  
6 227 cells positive for LAMP1, LC3A, LC3B, TFEB, Beclin-1, p62 and cathepsin B/D were similar in the  
7  
8  
9 228 bronchial lamina propria of COPD patients of different severity compared to CNS and CS (Table 3).

10  
11 229 No significant association emerged between the expression levels of autophagic molecules in  
12  
13 230 bronchial biopsies and smoking history or respiratory function.  
14  
15

### 16 17 231 *3.4 Immunohistochemistry of autophagic molecules in peripheral airways and lung parenchyma*

18  
19  
20 232 As shown in Table 4, no differences in the expression of LC3B, p62, TFEB, Beclin-1 and cathepsin  
21  
22 233 B/D were found in the bronchiolar epithelium of peripheral airways of COPD patients compared to  
23  
24 234 CNS and CS. In comparison to CS and COPD patients, CNS expressed significantly lower levels of  
25  
26 235 LC3A ( $p<0.01$  and  $p<0.05$ , respectively) (Figure 2a,b), total LC3 ( $p<0.01$ ) and LAMP1 ( $p<0.01$ )  
27  
28  
29 236 (Figure 2c,d). Similar results were found also in the analysis of alveolar macrophages and alveolar  
30  
31 237 septa (Table 4). Specifically, alveolar macrophages of CS and COPD patients expressed higher levels  
32  
33 238 of LC3A ( $p<0.01$ ) and total LC3 ( $p<0.01$ ) in comparison to CNS. A higher level of LAMP1 was  
34  
35  
36 239 found in CS in comparison to CNS ( $p<0.01$ ) but not to COPD patients. Concerning alveolar septa,  
37  
38 240 CNS expressed lower levels of LC3A ( $p<0.01$ ) (Figure 2a,b), total LC3 ( $p<0.01$ ) and LAMP1  
39  
40 241 ( $p<0.01$ ) in comparison to both CS and COPD patients (Table 4). Importantly, CNS showed also a  
41  
42  
43 242 lower number of p62 immunostained alveolar macrophages in comparison to CS and COPD patients  
44  
45 243 ( $p<0.01$  and  $p<0.05$ , respectively) (Table 4, Figure 3a,b). Double staining for LC3B (brown colour)  
46  
47 244 and p62 protein (red colour), performed in 3 COPD patients and 3 CNS, showed a clear p62  
48  
49  
50 245 immunoexpression in a large number of alveolar macrophages coexpressing LC3B in COPD lungs  
51  
52 246 (Figure 3c). On the other hand, the number of cathepsin B positive cell in alveolar septa was slightly  
53  
54 247 but significantly higher in CNS than in the other two groups ( $p<0.05$ ). Finally, the level of LC3B was  
55  
56  
57  
58  
59  
60



1  
2 248 higher in the alveolar septa of CNS than in CS ( $p<0.05$ ). No significant association emerged between  
3  
4 249 the expression levels of autophagic molecules and smoking history or respiratory function.  
5  
6

### 7 250 *3.5 ELISA tests for autophagic molecules in homogenized peripheral lung tissue*

9  
10 251 As shown in Table 5 and Figure 4, we found no differences in the concentration of LAMP1 and LC3A  
11  
12 252 in the lung tissue homogenates of the 3 groups. CNS showed a reduced level of LC3B in comparison  
13  
14  
15 253 to CS and COPD patients ( $p=0.02$ ). Importantly, patients with COPD were found to have a higher  
16  
17 254 level of p62 protein than CNS and CS ( $p=0.02$ ), confirming data obtained by immunohistochemistry,  
18  
19  
20 255 particularly in alveolar macrophages.  
21

## 22 256 **4. Discussion**

23  
24  
25 257 With this study, we sought to evaluate through multiple techniques the autophagic process in COPD  
26  
27 258 patients in different areas of the respiratory tract, comparing it with that of healthy subjects with or  
28  
29  
30 259 without smoking history.

31  
32 260 Our data point out that autophagy is more stimulated in smokers than in non-smokers, regardless of  
33  
34 261 the presence of COPD. We found this stimulation in the bronchial mucosa as well as in small airways  
35  
36 262 and lung parenchyma. As for the bronchial mucosa, this process was highlighted by an increase in  
37  
38  
39 263 LC3B-positive cells in smoking controls and severe/very severe COPD patients compared with non-  
40  
41 264 smokers. In peripheral airways and lung parenchyma, on the other hand, stimulation of the autophagic  
42  
43 265 process in smokers was indicated by increased LC3A, total LC3 and LAMP1 in bronchiolar  
44  
45  
46 266 epithelium, alveolar septa and alveolar macrophages. ELISA tests performed on lung tissue  
47  
48 267 homogenate confirmed these data, showing a higher concentration of LC3B in both COPD patients  
49  
50 268 and smoking subjects compared with CNS. Taken together, these findings strongly confirm previous  
51  
52  
53 269 data and point out that autophagy represents a response to smoke exposure [4,25,29,30]. Of note, the  
54  
55 270 increase in LAMP1 together with LC3 supports a real boost in autophagic flux and confirms the  
56  
57 271 proper functioning of the lysosomal system [4,5,29,30].  
58  
59  
60

1  
2 272 Intriguingly, the increase in autophagy seems to be independent of lung function deterioration, as it  
3  
4 273 was evident – and comparable – in both CS and COPD patients. However, an impaired autophagic  
5  
6 274 flux emerged in patients with COPD when compared with controls. This difference was only  
7  
8  
9 275 highlighted by ELISA test as an increased concentration in p62 level in the lung tissue homogenate  
10  
11 276 and in alveolar macrophages by immunohistochemistry. The increase of p62 in lung tissue of patients  
12  
13 277 with COPD has been reported previously and has been interpreted as a potential mechanism of  
14  
15  
16 278 impaired autophagy and proteostasis dysfunction, leading to COPD-emphysema development  
17  
18 279 [15,25,31-33]. Indeed, this autophagy defect, induced by cigarette smoke but not present in smokers  
19  
20 280 with a normal lung function, could play a proapoptotic function and underlie the loss of peripheral  
21  
22  
23 281 lung tissue, which is a feature of pulmonary emphysema [31-34]. Our data further support these  
24  
25 282 hypotheses. The absence of differences in LAMP1 concentration, despite the increase in LC3B, also  
26  
27 283 suggests an impairment in the lysosomal system.

28  
29  
30 284 On the other hand, transcriptomics analyses conducted on both bronchial tissue and lung parenchyma  
31  
32  
33 285 showed no significant differences in the expression of the mRNAs studied among the three groups.  
34  
35 286 Supporting these results is the lack of differences in immunohistochemical analysis of TFEB,  
36  
37 287 considered a tool for monitoring transcriptional regulation connected with autophagy [5]. This lack  
38  
39  
40 288 of differences might suggest that both stimulation and impairment of autophagic flux are primarily  
41  
42 289 post-transcriptional, but further studies are needed to confirm these findings.

43  
44  
45 290 Also of note, the increased positivity of alveolar macrophages for p62, is able to differentiates  
46  
47 291 smokers, both COPD and control subjects, from non-smokers. This finding confirms the results  
48  
49  
50 292 obtained by Monick *et al.* in a previous study [31]. Their data indicated an altered autophagic process  
51  
52 293 at the level of alveolar macrophages, induced by a defect in the delivery of autophagosomes to the  
53  
54 294 lysosome. However, as in our study, this defect was associated with an increased stimulus for  
55  
56 295 autophagy, which they highlighted by an increased number of autophagosomes in smoking patients  
57  
58  
59  
60

1  
2 296 compared with controls. This could be explained by an increased macrophage loading of poorly  
3  
4 297 digestible material, which may lead to a defect in autophagy/lysosomal function [35]. This finding  
5  
6 298 seems particularly interesting because impairment of autophagy in alveolar macrophages could also  
7  
8  
9 299 impair xenophagy, the autophagy involved in pathogen clearance [36]. As highlighted in previous  
10  
11 300 studies, impairment of xenophagy in macrophages could be one of the factors that explain the  
12  
13 301 increased incidence of respiratory infections in smokers [31,37], regardless of respiratory function.

15  
16 302 Our results can be analysed in light of other studies where bronchial epithelial cells were stimulated  
17  
18 303 with cigarette smoke [18,25,30]. In these studies, stimulation with cigarette smoke led to activation  
19  
20 304 of autophagy followed by accumulation of p62 and ubiquitinated proteins, which was interpreted as  
21  
22 305 impairment of the process and a precursor to cellular senescence [15]. Therefore, it can be  
23  
24  
25 306 hypothesized that different stimuli are capable of activating autophagy in HBECs (inflammation,  
26  
27 307 smoking exposure), but that only cigarette smoke is capable of leading to an impairment of the  
28  
29  
30 308 autophagic process with accumulation of p62 and ubiquitinated proteins, precursor of cellular  
31  
32 309 senescence. Indeed, it has been proposed that the increased baseline autophagy found in patients with  
33  
34 310 COPD is mainly due to oxidative stress and results in a reduced reserve of autophagy flux activation  
35  
36 311 in the bronchial epithelial cells of these patients. Confirming this, a significant decrease in autophagy  
37  
38  
39 312 induction in response to cigarette smoke exposure was found in bronchial epithelial cells isolated  
40  
41 313 from COPD patients when compared to those from non-smokers [15].

43  
44 314 This study has some strengths and limitations. The main strength is the use of multiple methods  
45  
46 315 simultaneously to reinforce the results obtained at protein level quantitation, and to study different  
47  
48  
49 316 stages of the autophagic process. Another strength is the analysis of these elements at different levels  
50  
51 317 of the respiratory system including different cell types, so that a more complete view of an extremely  
52  
53 318 complex system can be obtained. In contrast, one of the main limitations of the study is the absence  
54  
55  
56 319 of in vitro tests, dedicated to specific mechanistic actions, which could have further strengthened our  
57  
58  
59  
60

1  
2 320 findings. Another limitation is the use of archival material, which sometimes did not allow a more  
3  
4 321 detailed analysis or an equal distribution of the population within the groups for certain variables,  
5  
6 322 such as gender, inhaled therapy and time since smoking cessation.  
7  
8

9  
10 323 In conclusion, our study confirms by multiple techniques, all focused on mRNA and protein  
11  
12 324 quantitation, that cigarette smoke stimulates autophagy in different manners inside the respiratory  
13  
14 325 system. The increase in the autophagic flux seems to be independent of lung function deterioration,  
15  
16 326 but an impairment of the process emerged in COPD patients, ~~identifying autophagy failure as a~~  
17  
18 ~~potential factor leading to COPD development~~. A reduced reserve of autophagy flux activation due  
19 327  
20  
21 328 to oxidative stress may be one of the factors differentiating smokers with normal lung function from  
22  
23 329 COPD patients, but this hypothesis needs to be confirmed. The same process could make smokers  
24  
25 more prone to respiratory infections due to xenophagy impairment in alveolar macrophages. Both  
26 330  
27  
28 331 stimulation of autophagy and its deficiency appear primarily post-transcriptional, but further studies  
29  
30 332 are needed to confirm these findings.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1

2 333 **Tables**

3 334

4 335

5 336 **Table 1.** Clinical characteristics of subjects for immunohistochemistry studies on the bronchial

6 337 biopsies

7 338

8 338

9

10

11

12

13

14

15

16

17

18 339

19 340

20 341

21 342

22 343

23 344

24 345

25 346

26 347

27 347

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Groups	n	Age (y)	M/F	Ex/current smokers	Pack years	FEV <sub>1</sub> (% pred) pre-β <sub>2</sub>	FEV <sub>1</sub> (% pred) post-β <sub>2</sub>	FEV <sub>1</sub> /FVC (%)
Control non-smokers	12	63±13	8/4	0	0	117±18	ND	86±10
Control smokers	13	60±11	11/2	1/12	41±31	101±14	ND	81±6
COPD grades I and II (mild/moderate)	16	72±6	11/5	7/9	50±29	63±11 <sup>#</sup>	67±14	57±10 <sup>#</sup>
COPD grades III and IV (severe/very severe)	14	68±18	13/1	11/3	61±44	38±5 <sup>#&amp;</sup>	42±7	43±10 <sup>#&amp;</sup>

Data are expressed as mean ± standard deviation. Patients with COPD were classified according to the grades of severity of the Global Initiative for Chronic Obstructive Lung Disease 2011 (goldcopd.org) using only the severity of airflow obstruction. For patients with COPD, FEV<sub>1</sub>/FVC (%) are post-bronchodilator (β<sub>2</sub>) values. Abbreviations: COPD, chronic obstructive pulmonary disease; M, male; F, female, FEV<sub>1</sub>, forced expiratory volume in one second; FVC, forced vital capacity; ND, not determined. Statistical analysis: ANOVA test: #, p<0.0001, significantly different from control smokers with normal lung function and control never smokers; &, p<0.0001, significantly different from mild/moderate COPD.

**Table 2.** Clinical characteristics of subjects for immunohistochemistry studies on the peripheral lung tissue

Groups	n	Age (y)	M/F	Ex/Current smokers	Pack years	FEV <sub>1</sub> (% pred) pre-β <sub>2</sub>	FEV <sub>1</sub> (% pred) post-β <sub>2</sub>	FEV <sub>1</sub> /FVC (%)
Control non-smokers	11	71±10	5/6	---	---	115±15	ND	80±5
Control smokers	11	67±6	7/4	7/4	36±14	96±10	ND	74±4
Patients with COPD	12	69±6	11/1	10/2	51±39	72±16 <sup>#</sup>	79±14	59±9 <sup>#</sup>

Data are expressed as mean ± standard deviation. For patients with COPD, FEV<sub>1</sub>/FVC (%) are post-bronchodilator (β<sub>2</sub>) values. Abbreviations: COPD, chronic obstructive pulmonary disease; M, male; F, female; FEV<sub>1</sub>, forced expiratory volume in one second; FVC, forced vital capacity; ND, not determined. Statistical analysis: ANOVA test: #, p<0.0001, significantly different from control smokers with normal lung function and control never smokers.

For Review Only

1

2 356

3 357

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

**Table 3.** Immunohistochemistry of autophagic molecules in the bronchial biopsies of patients with COPD and control subjects.

Localization	Control non smokers N=12	Control smokers N=13	Mild/Moderate COPD N=16	Severe/very severe COPD N=14	Kruskal Wallis (p value)
<b>Epithelium</b>					
<b>Score (0-3)</b>					
<b>LC3A</b>	0.25 (0.25-0.5)	0 (0-0.75)	0.5 (0-1)	0.25 (0-1)	0.066
<b>LC3B</b>	1.5 (0.5-3)	2.5 (1.5-2.5)§	1.75 (1-2.5)	2.5 (1.5-3)*&	<b>0.020</b>
<b>TFEB total</b>	0.0 (0.0-0.5)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.925
<b>Cathepsin B</b>	0 (0-0)	0 (0-0)	0 (0-0)	0 (0-0)	ND
<b>Cathepsin D</b>	0.87 (0.75-1.25)	1 (0.5-1.5)	1.5 (0.75-2)	1.37 (0.75-1.5)	0.131
<b>Beclin-1</b>	1.5 (1.5-1.5)	1.5 (1-2)	1.5 (1.5-2)	1.5 (1.5-2.5)	0.742
<b>P62</b>	0.37 (0-0.5)	0.75(0.25-1.5)	0.5(0.25-1)	0.5(0.25-1)	0.359
<b>LAMP1</b>	1.0(0.5-1.5)	0.75(0.25-1)	0.75(0.25-1.5)	0.75(0.5-1)	0.377
<b>Lamina propria cells/mm<sup>2</sup></b>					
<b>LC3A</b>	8 (0-13)	4 (0-26)	9.5 (0-55)	13 (0-24)	0.373
<b>LC3B</b>	70 (32-200)	69 (21-97)	78 (16-118)	71 (29-156)	0.794
<b>TFEB total</b>	0.0 (0.0-34.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.953
<b>Cathepsin B</b>	4 (0-8)	5 (0-13)	0 (0-24)	0 (0-32)	0.494
<b>Cathepsin D</b>	12.5 (8-48)	47.5 (9-97)	41.5 (11-64)	38 (12-97)	0.256
<b>Beclin-1</b>	39 (9-81)	19.5 (0-92)	42 (0-87)	11 (5-124)	0.729
<b>P62</b>	32(5-74)	35(16-118)	13(0-56)	20(0-90)	0.098
<b>LAMP1</b>	216(142-322)	200(165-226)	208(78-274)	193(134-240)	0.564

Data are expressed as median and range. Abbreviations: COPD, chronic obstructive pulmonary disease; LC3, microtubule-associated protein 1A/1B-light chain 3; TFEB, transcription factor EB; LAMP1, lysosome-associated membrane protein 1; ND, not determined. Statistical analysis: Mann Whitney U test: \*, p=0.028 vs mild/moderate COPD; &, p=0.014 vs control non-smokers; §, p=0.0423 vs control non-smokers.



**Table 4.** Immunohistochemical quantification of autophagic molecules in the peripheral lung of patients with COPD, in control smokers and non-smoking subjects

Localization	Control non-smokers N=11	Control smokers N=11	Patients with COPD N=12	Kruskal Wallis (p value)
<b>Bronchiolar epithelium (score 0-3)</b>				
LC3A	0.40 (0.25-1.0)	1.50 (0.75-2.0)&	1.25 (0.5-2.0)*	<b>0.0013</b>
LC3B	2.50 (1.9-2.75)	2.75 (2.0-3.0)	2.75 (2.5-3.0)	0.287
LC3 (A+B)	2.75 (2.15-3.75)	3.95 (2.75-4.75) &	4 (3.24-4.5) &	<b>0.028</b>
TFEB total	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	ND
Cathepsin B	0.12 (0-0.50)	0.0 (0.0-0.50)	0.0 (0.0-0.12)	0.218
Cathepsin D	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	ND
Beclin-1	2.32 (2.0-2.5)	2.50 (1.5-2.75)	2.5 (1.5-2.75)	0.214
P62	0.0 (0.0-0.0)	0.0 (0.0-0.12)	0.0 (0.0-0.0)	0.715
LAMP1	0.12 (0.0-0.25)	1.0 (0.37-1.50)&	0.55 (0.5-0.75)&	<b>&lt;0.0001</b>
<b>Alveolar macrophages (score 0-3)</b>				
LC3A	0.5 (0.25-1.0)	1.5 (1.0-2.0)&	1.25 (1.0-1.25)&	<b>0.0001</b>
LC3B	2.0 (1.5-2.5)	2.0 (1.75-2.5)	2.0 (2-2.5)	0.237
LC3 (A+B)	2.5 (1.75-3)	3.5 (3-4.5) &	3.25 (3-3.75) &	<b>0.0004</b>
TFEB total	0.0 (0.0-1.4)	0.05 (0.0-1.6)	0.0 (0.0-1.5)	0.7342
TFEB nuclear	0.0 (0.0-0.35)	0.0 (0.0-0.27)	0.0 (0.0-0.24)	0.6924
TFEB cytoplasmic	0.0 (0.0-1.05)	0.05 (0.0-1.5)	0.0 (0.0-1.5)	0.7260
Cathepsin B	0.12 (0.12-0.75)	0.50 (0.0-1.75)	0.31 (0.12-1.5)	0.640
Cathepsin D	0.0 (0.0-0.25)	0.0 (0.0-0.50)	0.10 (0.0-0.50)	0.980
Beclin-1	1.5 (1.25-2.0)	1.75 (1.25-2.0)	1.62 (1.25-2.0)	0.272
P62	0.0 (0.0-0.12)	0.50 (0.5-1.0)&	0.50 (0.0-1.0)*	<b>0.0009</b>
LAMP1	1.5 (0.75-2.0)	2.0 (1.5-2.5)&	1.5 (1.5-2.0)	<b>0.021</b>
<b>Alveolar septa (score 0-3)</b>				
LC3A	0.0 (0.0-0.5)	1.0 (0.75-1.25)&	1.0 (1.0-1.0)&	<b>&lt;0.0001</b>
LC3B	2.0 (1.5-2.5)	1.75 (1.5-2.0)*	2.0 (1.75-2.0)	<b>0.022</b>
LC3 (A+B)	2.5 (1.5-2.5)	3 (2.25-3) &	3 (2.75-3) &	<b>0.0007</b>
TFEB total	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	ND
Cathepsin B	0.12 (0.0-0.50)	0.0 (0.0-0.12)*	0.0 (0.0-0.5)*	<b>0.041</b>
Cathepsin D	0. (0.0-0.12)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.890
Beclin-1	1.5 (1.25-2.0)	1.5 (1.25-2.0)	1.62 (1.5-1.75)	0.722
P62	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	ND

<b>LAMP1</b>	0.75 (0.25-1.0)	1.0 (1.0-1.5)&	1.0 (1.0-1.0)&	<b>0.0021</b>
--------------	-----------------	----------------	----------------	---------------

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

365 Data are expressed as median and range. Abbreviations: COPD, chronic obstructive pulmonary  
366 disease; LC3, microtubule-associated protein 1A/1B-light chain 3; TFEB, transcription factor EB;  
367 LAMP1, lysosome-associated membrane protein 1; ND, not determined. Statistical analysis: ; Mann  
368 Whitney U test: \*,  $p < 0.05$  vs control non-smokers; &,  $p < 0.01$  vs control non-smokers.

For Review Only

**Table 5.** ELISA tests for autophagic molecules in the lung parenchyma of control non-smokers, control smokers and patients with COPD.

Proteins	Control non-smokers N=11	Control smokers N=11	Patients with COPD N=10	Kruskal Wallis (p value)
LC3A (ng/mL)	334 (188.5-835.5)	438 (25.50-700)	405.5 (63.50-1048)	0.9976
LC3B (ng/mL)	720 (405-1105)	1235 (545-1985)*	1200 (490-3625)*	<b>0.0230</b>
LC3A+LC3B (ng/ml)	1184 (820-1520)	1586 (816-2564)*	1768 (716-4470)*	<b>0.0333</b>
LAMP1 (ng/mL)	679 (223-2752)	966.5 (230.5-2687)	705.5 (179-4352)	0.5941
P62 (ng/mL)	0 (0.00-15.85)	0 (0.00-18.55)	12.15 (0.00-33.45)*&	<b>0.0231</b>

Data are expressed as median and range. Abbreviations: COPD, chronic obstructive pulmonary disease; LC3, microtubule-associated protein 1A/1B-light chain 3; LAMP1, lysosome-associated membrane protein 1. Statistical analysis: ; Mann Whitney U test: \*, p<0.05 vs control non-smokers; &, p<0.05 vs control smokers.

## References

1. Mizushima N, Komatsu M. Autophagy: Renovation of cells and tissues. *Cell* 2011; 147: 728–741.
2. Barnes PJ, Baker J, Donnelly LE. Autophagy in asthma and chronic obstructive pulmonary disease. *Clin. Sci.* 2022; 136: 733–746.
3. Zeng X, Overmeyer JH, Maltese WA. Functional specificity of the mammalian Beclin-Vps34 PI 3-kinase complex in macroautophagy versus endocytosis and lysosomal enzyme trafficking. *J. Cell Sci.* 2006; 119: 259–270.
4. Bonam SR, Bayry J, Tschan MP, *et al.* Progress and Challenges in The Use of MAP1LC3 as a Legitimate Marker for Measuring Dynamic Autophagy In Vivo. *Cells* 2020; 9: 1321.
5. Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, *et al.* Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)<sup>1</sup>. *Autophagy* 2021; 17: 1–382.
6. Chen Y, Li Q, Li Q, *et al.* p62/SQSTM1, a Central but Unexploited Target: Advances in Its Physiological/Pathogenic Functions and Small Molecular Modulators. *J. Med. Chem.* 2020; 63: 10135–10157.
7. Levine B, Kroemer G. Autophagy in the Pathogenesis of Disease. *Cell* 2008; 132: 27–42.
8. Zhao X, Zhang Q, Zheng R. The interplay between oxidative stress and autophagy in chronic obstructive pulmonary disease. *Front. Physiol.* 2022; 13: 1–15.
9. Di Stefano A, Gnemmi I, Dossena F, *et al.* Pathogenesis of COPD at the cellular and molecular level. *Minerva Med.* 2022; 113: 405–423.
10. Agusti A, Celli BR, Criner GJ, *et al.* Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. *ERJ* 2023; 61 (4): 2300239.
11. Fujita Y, Araya J, Ito S, *et al.* Suppression of autophagy by extracellular vesicles promotes myofibroblast differentiation in COPD pathogenesis. *J. Extracell. Vesicles* 2015; 4: 28388.
12. Jati S, Kundu S, Chakraborty A, *et al.* Wnt5A signaling promotes defense against bacterial pathogens by activating a host autophagy circuit. *Front. Immunol.* 2018; 9: 679.
13. Kuwano K, Araya J, Hara H, *et al.* Cellular senescence and autophagy in the pathogenesis of chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). *Respir. Investig.* 2016; 54: 397–406.
14. Jiang S, Sun J, Mohammadtursun N, *et al.* Dual role of autophagy/mitophagy in chronic obstructive pulmonary disease. *Pulm. Pharmacol. Ther.* 2019; 56: 116–125.
15. Fujii S, Hara H, Araya J, *et al.* Insufficient autophagy promotes bronchial epithelial cell senescence in chronic obstructive pulmonary disease. *Oncoimmunology* 2012; 1: 630–641.
16. Mizumura K, Maruoka S, Shimizu T, *et al.* Autophagy, selective autophagy, and necroptosis in COPD. *Int. J. COPD* 2018; 13: 3165–3172.
17. Lam HC, Cloonam SM, Bhashyam AR, *et al.* Histone deacetylase 6-mediated selective autophagy regulates copd-associated cilia dysfunction. *J. Clin. Invest.* 2013; 123: 5212–5230.
18. Li Y, Yu G, Yuan S, *et al.* 14,15-Epoxyeicosatrienoic acid suppresses cigarette smoke condensate-induced inflammation in lung epithelial cells by inhibiting autophagy. *Am. J. Physiol. - Lung Cell. Mol. Physiol.* 2016; 311: L970–L980.
19. Wang Y, Liu J, Zhou J, *et al.* MTOR Suppresses Cigarette Smoke-Induced Epithelial Cell Death and Airway Inflammation in Chronic Obstructive Pulmonary Disease. *J. Immunol.* 2018; 200: 2571–2580.
20. Zhou JS, Zhao Y, Zhou HB, *et al.* Autophagy plays an essential role in cigarette smoke-induced expression of MUC5AC in airway epithelium. *Am. J. Physiol. - Lung Cell. Mol. Physiol.* 2016; 310: L1042–L1052.
21. Bialik S, Dasari SK, Kimchi A. Autophagy-dependent cell death - where, how and why a

- 1  
2 423 cell eats itself to death. *J. Cell Sci.* 2018; 131: jcs215152.
- 3 424 22. Gouzi F, Blaquièrre M, Catteau M, et al. Oxidative stress regulates autophagy in cultured  
4 425 muscle cells of patients with chronic obstructive pulmonary disease. *J. Cell. Physiol.* 2018;  
5 426 233: 9629–9639.
- 6 427 23. Guo Y, Gosker HR, Schols AMWJ, et al. Autophagy in locomotor muscles of patients with  
7 428 chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* 2013; 188: 1313–  
8 429 1320.
- 9 430 24. Tan WSD, Shen HM, Wong WSF. Dysregulated autophagy in COPD: A pathogenic process  
10 431 to be deciphered. *Pharmacol. Res.* 2019; 144: 1–7.
- 11 432 25. Vij N, Chandramani-Shivalingappa P, Van Westphal C, et al. Cigarette smoke-induced  
12 433 autophagy impairment accelerates lung aging, copd-emphysema exacerbations and  
13 434 pathogenesis. *Am. J. Physiol. - Cell Physiol.* 2018; 314: C73–C87.
- 14 435 26. Bodas M, Vij N. Augmenting autophagy for prognosis based intervention of COPD-  
15 436 pathophysiology. *Respir. Res.* 2017; 18: 1–8.
- 16 437 27. Di Stefano A, Caramori G, Barczyk A, et al. Innate immunity but not NLRP3  
17 438 inflammasome activation correlates with severity of stable COPD. *Thorax* 2014; 69: 516–  
18 439 524.
- 19 440 28. Sauler M, McDonough JE, Adams TS, et al. Characterization of the COPD alveolar niche  
20 441 using single-cell RNA sequencing. *Nat. Commun.* 2022; 13: 494.
- 21 442 29. Bartlett BJ, Isakson P, Lewerenz J, et al. p62, Ref(2)P and ubiquitinated proteins are  
22 443 conserved markers of neuronal aging, aggregate formation and progressive autophagic  
23 444 defects. *Autophagy* 2011; 7: 572–583.
- 24 445 30. Chen ZH, Kim HP, Sciruba FC, et al. Egr-1 regulates autophagy in cigarette smoke-induced  
25 446 chronic obstructive pulmonary disease. *PLoS One* 2008; 3(10): e3316.
- 26 447 31. Monick MM, Powers LS, Walters K, et al. Identification of an Autophagy Defect in  
27 448 Smokers' Alveolar Macrophages. *J. Immunol.* 2010; 185: 5425–5435.
- 28 449 32. Tran I, Ji C, Ni I, et al. Role of cigarette smoke-induced aggresome formation in chronic  
29 450 obstructive pulmonary disease-emphysema pathogenesis. *Am. J. Respir. Cell Mol. Biol.*  
30 451 2015; 53: 159–173.
- 31 452 33. Mercado N, Colley T, Baker JR, et al. Bicaudal D1 impairs autophagosome maturation in  
32 453 chronic obstructive pulmonary disease. *FASEB BioAdvances* 2019; 1: 688–705.
- 33 454 34. Hong PK, Wang X, Chen ZH, et al. Autophagic proteins regulate cigarette smoke-induced  
34 455 apoptosis: Protective role of heme oxygenase-1. *Autophagy* 2008; 4: 887–895.
- 35 456 35. Montgomery RR, Webster P, Mellman I. Accumulation of indigestible substances reduces  
36 457 fusion competence of macrophage lysosomes. *J. Immunol.* 1991; 147: 3087–3095.
- 37 458 36. Levine B. Eating oneself and uninvited guests: Autophagy-related pathways in cellular  
38 459 defense. *Cell* 2005; 120: 159–162.
- 39 460 37. Zheng YT, Shahnazari S, Brech A, et al. The Adaptor Protein p62/SQSTM1 Targets  
40 461 Invading Bacteria to the Autophagy Pathway. *J. Immunol.* 2009; 183: 5909–5916.
- 41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 467 **Figure legends**

3 468

4  
5 469 **Figure 1**

6  
7  
8 470 Expression levels of selected autophagy genes obtained in bronchial rings (a) and lung parenchyma  
9  
10 471 (b) of control non-smokers (CNS), control smokers (CS) patients with chronic obstructive pulmonary  
11  
12 472 disease (COPD). The box plot showed the median and the distribution of expression values per gene.  
13  
14  
15 473 Abbreviations: TEFB, Transcription Factor EB; CTSB, Cathepsin B; CTSD, Cathepsin D; LAMP1,  
16  
17 474 Lysosomal-associated membrane protein 1; MAP1LC3B, Microtubule Associated Protein 1 Light  
18  
19 475 Chain 3 Beta; BECN1, Beclin 1; NUP62, Nucleoporin 62; MAP1LC3B, Microtubule Associated  
20  
21  
22 476 Protein 1 Light Chain 3 Alpha.

23

24 477

25

26 478 **Figure 2**

27  
28 479 Photomicrographs showing bronchiolar epithelium, alveolar macrophages and alveolar septa of  
29  
30 480 control non-smokers (a,c) and COPD patients (b,d) immunostained for identification of LC3A (a,b)  
31  
32 481 and LAMP1 (c,d). Results for single stainings are representative of those from 11 non-smokers and  
33  
34 482 12 mild/moderate COPD patients. An increased immunopositivity for LC3A and for LAMP1 was  
35  
36 483 observed in bronchiolar epithelium (BE), alveolar macrophages (arrows) and alveolar septa  
37  
38 484 (arrows) in COPD patients. CNS=Control Non Smokers, COPD=Chronic Obstructive Pulmonary  
39  
40 485 Disease; Bars=30  $\mu$ m.

41

42 486

43

44

45 487 **Figure 3**

46  
47 488 Photomicrographs showing alveolar macrophages and alveolar septa (a,b) of control non-smokers (a)  
48  
49 489 and COPD patients (b) immunostained for identification of p62 (a,b). Panel c shows double stained  
50  
51 490 macrophages from a patient with COPD showing immunopositivity for p62 (red colour) and LC3B  
52  
53 491 (brown colour), the most expressed autophagy marker in alveolar macrophages. Results for single  
54  
55

56

57

58

59

60

1  
2 492 staining are representative of those from 11 non-smokers and 12 mild/moderate COPD patients.  
3  
4 493 Double staining was performed in 3 control non-smokers and in 3 patients with COPD. Arrows  
5  
6 494 indicate single or double-immunostained alveolar macrophages. An increased immunopositivity for  
7  
8  
9 495 p62 antigen is shown in COPD patients compared to control non-smokers. Bars=30 microns (a,b) and  
10  
11 496 15 microns (c).

12  
13 497  
14  
15  
16 498 **Figure 4**

17  
18 499 Quantitation by ELISA tests of LC3A (a), LC3B (b), LC3A+LC3B (c), LAMP1 (d) and p62 (e)  
19  
20 500 molecules in the lung protein extracts of control non-smokers (CNS, n=11), control smokers (CS,  
21  
22 n=11) and patients with chronic obstructive pulmonary disease (COPD, n=12). LC3B and  
23 501 LC3A+LC3B showed higher values in COPD and CS compared to CNS (b,c). P62 was increased in  
24  
25 502 COPD patients compared to CS and CNS (e). Data are expressed as mean  $\pm$  standard errors. Mann  
26  
27 503 Whitney was used test for comparison between groups.  
28  
29  
30 504  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



# 1 **Impaired autophagy in the lower airways and lung parenchyma in stable COPD**

2 Stefano Levra MD<sup>1</sup>, Umberto Rosani PhD<sup>2</sup>, Isabella Gnemmi<sup>3</sup>, Paola Brun PhD<sup>4</sup>, Andrea Leonardi  
3 MD<sup>5</sup>, Vitina Carriero PhD<sup>1</sup>, Francesca Bertolini PhD<sup>1</sup>, Bruno Balbi MD<sup>6</sup>, Mirella Profita PhD<sup>7</sup>,  
4 Fabio Luigi Massimo Ricciardolo MD<sup>1,7,8\*</sup>, Antonino Di Stefano PhD<sup>3\*</sup>.

5 <sup>1</sup>Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, Italy.

6 <sup>2</sup>Department of Biology, University of Padova, via U. Bassi 58/b, 35121 Padova. <sup>3</sup>Divisione di  
7 Pneumologia e Laboratorio di Citoimmunopatologia dell'Apparato Cardio Respiratorio, Istituti  
8 Clinici Scientifici Maugeri, IRCCS, Veruno, Novara, Italy. <sup>4</sup>Department of Molecular Medicine,  
9 Histology Unit, University of Padova, Padova, Italy. <sup>5</sup>Department of Neuroscience, Ophthalmology  
10 Unit, University of Padova, Padova, Italy. <sup>6</sup>Mondomedico, Borgomanero, Novara, Italy. <sup>7</sup>Institute  
11 of Translational Pharmacology, National Research Council (IFT-CNR), Section of Palermo,  
12 Palermo, Italy, <sup>8</sup>Severe Asthma and Rare Lung Disease Unit, San Luigi Gonzaga University  
13 Hospital, Orbassano, Turin, Italy

14  
15 \*These authors contributed equally to the present work

16  
17  
18 Correspondence to:

19  
20 Antonino Di Stefano, PhD  
21 Istituti Clinici Scientifici Maugeri, IRCCS  
22 Laboratorio di Citoimmunopatologia  
23 dell'Apparato Cardio Respiratorio  
24 Via per Revislate, 13  
25 28010 Veruno (NO), Italy  
26 Tel: +39 0322 884711  
27 Fax: +39 0322 884776  
28 E-mail: [antonino.distefano@icsmaugeri.it](mailto:antonino.distefano@icsmaugeri.it)

## 29 30 31 32 33 **Keywords**

34 COPD, autophagic stimulus, autophagy impairment, smoke, rehabilitation, inflammation

## 35 36 37 38 39 **Abbreviations**

40 BECN1, beclin-1

41 CNS, control non-smokers

42 COPD, chronic obstructive pulmonary disease

43 CS, control smokers with normal lung function

1  
2 41 CTSB, cathepsin B  
3  
4 42 CTSD, cathepsin D  
5  
6 43 ELISA, enzyme-linked immunosorbent assay  
7  
8 44 FEV<sub>1</sub>, forced expiratory volume in one second  
9  
10 45 FVC, forced vital capacity  
11  
12 46 GOLD, Global Initiative for Chronic Obstructive Lung Disease  
13  
14 47 HBEC, human bronchial epithelial cell  
15  
16 48 LAMP1, lysosome-associated membrane protein 1  
17  
18 49 MAP1LC3 (LC3), microtubule-associated protein 1A/1B-light chain 3  
19  
20 50 MCOPD, mild/moderate chronic obstructive pulmonary disease  
21  
22 51 NUP62 (p62), nucleoporin 62  
23  
24 52 PI3K, phosphoinositide-3-kinase  
25  
26 53 SCOPD, severe/very severe chronic obstructive pulmonary disease  
27  
28 54 TFEB, transcription factor EB  
29  
30 55 VPS34, vacuolar protein sorting 34

31  
32 57 **Acknowledgements:** this work was supported, in part, by Istituti Clinici Scientifici Maugeri, SpA,  
33  
34 58 SB, IRCCS, Ricerca Corrente, and, in part, by Department of Clinical and Biological Sciences,  
35  
36 59 University of Turin, Orbassano, Turin, Italy.

37  
38 60 **Author contributions:** ADS, SL, UR and FLMR contributed in writing and revising the manuscript;  
39  
40 61 IG, VC, FB, MP and PB, contributed to the production of the data and accuracy of the data analysis;  
41  
42 62 AL and BB contributed to a critical revision of the manuscript.

43  
44 63 **Conflict of Interest:** All authors declare absence of any conflict of interest concerning this study

#### 45 64 **Ethics approval and consent to participate**

46 65 This study was approved by the Istituti Clinici Scientifici Maugeri (protocol p112) and by Ethical  
47  
48 66 Committee of the San Luigi Gonzaga University Hospital (protocol n. 9544/2019) and performed  
49  
50 67 following the Declaration of Helsinki. Written informed consent was received from all patients  
51  
52 68 before inclusion in the study.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60**Abstract**

71

**Background.** There is increasing evidence of autophagy activation in COPD, but its role is complex and probably regulated through cell type-specific mechanisms. This study aims to investigate the autophagic process at multiple levels within the respiratory system, using different methods to clarify conflicting results reported so far.

**Methods.** This cross-sectional study was performed on bronchial biopsies and peripheral lung samples obtained from COPD patients (30 and 12 per sample type, respectively) and healthy controls (25 and 22 per sample type, respectively), divided by smoking history. Subjects were matched for age and smoking history. We analysed some of the most important proteins involved in autophagosome formation, such as LC3 and p62, as well as some molecules essential for lysosome function, such as LAMP1. Immunohistochemistry was used to assess the autophagic process in both sample types. ELISA and transcriptomic analysis were performed on lung samples.

**Results.** We found increased autophagic stimulus in smoking subjects, regardless of respiratory function. This was revealed by immunohistochemistry through a significant increase in LC3 ( $p < 0.01$ ) and LAMP1 ( $p < 0.01$ ) in small airway bronchiolar epithelium, alveolar septa, and alveolar macrophages. Similar results were obtained in bronchial biopsy epithelium by evaluating LC3B ( $p < 0.05$ ), also increased in homogenate lung tissue using ELISA ( $p < 0.05$ ). Patients with COPD, unlike the others, showed an increase in p62 by ELISA ( $p < 0.05$ ). No differences were found in transcriptomics analysis.

**Conclusions.** Different techniques, applied at post-transcriptional level, confirm that cigarette smoke stimulates autophagy at multiple levels inside the respiratory system, and that autophagy failure may characterise COPD.

93

94 Word count: 250

95

96

97

98

99

100

101

102

103

104

105

106

## 1. Introduction

Autophagy is a pivotal process in cellular homeostasis, contributing to the regulation of intracellular component processing and recycling [1]. There are several forms of autophagy, but three are classically recognized: macroautophagy, microautophagy, and chaperone-mediated autophagy [1].

Macroautophagy is the main form of autophagy and starts with the creation of transient double membrane vesicles called autophagosomes. The process requires the formation of an isolated membrane by a Class III phosphoinositide-3-kinase (PI3K) complex, which includes proteins such as Beclin-1 and vacuolar protein sorting 34 (VPS34) [2,3]. The PI3K complex also induces nuclear localization of the transcription factor EB (TFEB), which activates several lysosomal and autophagy-related genes [2]. The isolated membrane then elongates to form a double crescent-shaped membrane called the phagophore. Further elongation and closure of the phagophore to form the autophagosome vesicle requires the presence of a protein called microtubule-associated protein 1A/1B-light chain 3 (MAP1LC3 or LC3) [4]. It is initially synthesized in a form called pro-LC3, which is converted to a proteolytically processed form called LC3A and finally modified through lipidation into LC3B [5]. Another protein deemed necessary to autophagosome formation and proper function is p62 (sequestosome-1, SQSTM1), which binds to LC3 and also to ubiquitinated proteins and organelles designated for degradation [2,6]. Through this mechanism, the cargo is incorporated into the autophagosome vesicle for transport to the lysosome, resulting in the degradation of its contents by lysosomal acid hydrolases. Several proteins essential for the proper functioning of the lysosome have been identified, including cathepsins and the lysosome-associated membrane protein 1 (LAMP1), which is also required for the proper fusion of lysosomes with autophagosomes [7].

In the last years, evidence has emerged regarding autophagy activation in Chronic Obstructive Pulmonary Disease (COPD) [2,8,9], a heterogeneous lung condition characterized by chronic respiratory symptoms and persistent airflow obstruction [10]. This activation is deemed to be mainly due to cigarette smoking, as induced autophagy is considered fundamental in maintaining cellular

1  
2 128 homeostasis in adverse environments. Indeed, it can preserve lung function through several  
3  
4 129 mechanisms, such as the inhibition of cellular senescence, the degradation of damaged organelles,  
5  
6 130 the suppression of myofibroblast differentiation, and the elimination of pathogens [11-15].  
7  
8  
9 131 Nevertheless, autophagy is a highly dynamic process and if excessive can become harmful [13,16].  
10  
11 132 Activated autophagy has been in fact linked to aberrant inflammatory response, mucus  
12  
13 133 hyperproduction, mucociliary clearance impairment, and cell death [17-21].  
14  
15  
16 134 Data on autophagy based on human bronchial epithelial cells (HBECs) and lung tissues from COPD  
17  
18 135 patients are conflicting, and there is no unifying explanation for these discrepancies. The role of  
19  
20 136 autophagy in COPD is considered complex and probably regulated via cell type specific mechanisms  
21  
22 [13,14,17,22,23]. Being both beneficial and harmful, autophagy can be considered as a double-edged  
23 137 sword [24]. A prognostic role has also been attributed to autophagy in COPD patients and the use of  
24  
25 138 drugs able to modulate the process has been hypothesized [19,25,26]. However, a better  
26  
27 139 understanding of changes in the autophagic process in response to cigarette smoke is deemed  
28  
29 140 necessary before considering this process as a therapeutic target in COPD [16].  
30  
31  
32 141 Considering the above, the purpose of this study is to investigate the autophagic process at different  
33  
34 142 levels within the respiratory system, comparing data obtained by multiple methods to achieve greater  
35  
36 143 robustness and try to better understand the conflicting results reported so far. A deeper knowledge of  
37  
38 144 the mechanisms of activation and dysregulation of autophagy in different areas of the respiratory  
39  
40 145 system and in different cell types could lead to the use of new specific drugs that can regulate the  
41  
42 146 autophagic process in a targeted manner to achieve optimal levels [2].  
43  
44  
45  
46 147  
47  
48 148  
49

## 50 149 **2. Methods**

### 51 52 150 *2.1 Subjects*

53  
54  
55 151 Archival material from COPD patients and healthy controls was used in the present study [27]. All  
56  
57 152 subjects were recruited from the Respiratory Medicine Unit of the “Istituti Clinici Scientifici  
58  
59  
60

1  
2 153 Maugeri” (Veruno, Italy) and the Department of Clinical and Biological Sciences of the San Luigi  
3  
4 154 Gonzaga University Hospital (Orbassano, Italy). The study complies with the Declaration of Helsinki  
5  
6 155 and has been approved by the Institutional Review Boards of Istituti Clinici Scientifici Maugeri  
7  
8  
9 156 (protocol p112) and by Ethical Committee of the San Luigi Gonzaga University Hospital (protocol  
10  
11 157 n. 9544/2019). All patients have signed an informed consent.  
12

### 13 158 *2.2 Lung function tests and volumes*

15  
16 159 Pulmonary function tests were performed in all subjects, according to current guidelines (see online  
17  
18 160 supplement for details). The severity of the airflow obstruction in COPD patients was staged using  
19  
20 161 GOLD criteria [www.goldcopd.org].  
21

### 22 162 *2.3 Samples collection*

23  
24  
25 163 A fiberoptic bronchoscopy has been performed to collect bronchial biopsies from segmental and  
26  
27 164 subsegmental airways (4<sup>th</sup> to 6<sup>th</sup> airway generation) of 55 subjects, 30 of whom with COPD (see  
28  
29  
30 165 online supplement for details). Thirty-four subjects undergoing lung resection surgery for a solitary  
31  
32 166 peripheral neoplasm have been recruited, including 12 with COPD. All with mild or moderate disease  
33  
34 167 severity, according to the eligibility criteria for surgery. Specimens of their lung parenchyma were  
35  
36 168 frozen and used for analysis (see online supplement for details). All COPD patients were stable and  
37  
38  
39 169 had not been treated with theophylline, antibiotics, antioxidants, mucolytics, and/or glucocorticoids  
40  
41 170 in the month prior to bronchoscopy or surgery.  
42

### 43 171 *2.4 Immunohistochemistry in bronchial and peripheral lung tissue*

44  
45  
46 172 Bronchial biopsies as well as peripheral lung specimens were used for immunohistochemical analysis.  
47  
48 173 Sections from each sample were stained with antibodies specific for autophagy markers and proteins  
49  
50 174 (see online supplement for details). In particular for LC3A, LC3B, cathepsin B, cathepsin D, beclin-  
51  
52 175 1, p62, LAMP1 and TFEB. The immunostaining for all the antigens studied was scored in the intact  
53  
54  
55 176 bronchial epithelium, as well as in the lamina propria. All bronchioles, alveolar macrophages and  
56  
57  
58  
59  
60

1  
2 177 alveolar septa observed in each lung section specimen were also analysed (see online supplement for  
3  
4 178 details).

### 6 179 *2.5 RNA extraction, sequencing and analysis from bronchial and peripheral lung tissue*

8  
9 180 Frozen lung parenchymal tissues used for immunohistochemical analysis and bronchial rings from  
10  
11 181 the same patients were also used for RNA extraction, sequencing and gene expression analysis (see  
12  
13 182 online supplement for details). We considered the expression levels of MAP1LC3A, MAP1LC3B,  
14  
15 183 CTSB, CTSD, BECN1, NUP62, LAMP1 and TFEB genes. The expression level of these genes was  
16  
17 184 also evaluated in <http://www.copdcellatlas.com/>, a COPD-dedicated gene expression browser of  
18  
19  
20 185 single-cell RNA sequencing data [28].

### 22 186 *2.6 ELISA tests in peripheral lung specimens*

24  
25 187 LC3A, LC3B, LAMP1 and p62 proteins quantification was performed in the lung tissue homogenates  
26  
27 188 obtained from frozen tissue specimens used also for immunohistochemical and RNA analysis (see  
28  
29 189 online supplement for details). The choice of molecules analysed by ELISA was made on the basis  
30  
31 190 of the differences revealed by immunohistochemistry.

### 34 191 *2.7 Statistical analysis*

36  
37 192 Group data were expressed as mean (standard deviation) for functional data or median (range) or  
38  
39 193 interquartile range (IQR) for morphologic data. Differences between groups were analysed using  
40  
41 194 analysis of variance (ANOVA) for functional data. ANOVA was followed by an unpaired t-test for  
42  
43 195 comparison between groups. The Kruskal Wallis test was applied to the morphologic data and  
44  
45 196 followed, in case of a significant result, by a Mann-Whitney U-test for comparison between groups.  
46  
47 197 Correlation coefficients were calculated using the Spearman rank method. Results were considered  
48  
49 198 statistically significant for  $p < 0.05$ . Data analysis was performed using the Stat View SE Graphics  
50  
51 199 program (Abacus Concepts Inc., Berkeley, CA-USA).

54  
55 200

56  
57 201

58  
59  
60



### 3. Results

#### 3.1 Population of the study

Bronchial biopsies were obtained from 30 COPD patients and 25 control subjects, 13 of whom had a significant smoking history. The characteristics of all these subjects are reported in Table 1. Peripheral lung samples were obtained from lung resections of 34 subjects, whose characteristics are shown in Table 2. Twelve of these had COPD, while the other 22 had normal lung function. Half of the control subjects were smokers.

#### 3.2 Gene expression level in bronchial rings and lung parenchyma

We examined RNA-seq expression data of 18 samples of bronchial rings and 23 lung parenchyma samples, which were obtained from frozen blocks adjacent to the specimens used for immunohistochemical analysis and from frozen bronchial rings (Figure 1). Considering MAP1LC3A, MAP1LC3B, CTSB, CTSD, BECN1, NUP62, LAMP1 and TFEB genes, no significant differences emerged in their expression levels between COPD, CS and CNS samples. CTSD resulted to be the gene with the highest expression among the 8 selected ones in both tissues, with increasing expression in CS and COPD compared to CNS. Similarly, CTSB also showed considerable expression levels in both tissues, although the increasing trend is less evident. LAMP1 showed moderate expression levels in lung parenchyma only, whereas the expression of MAP1LC3A, MAP1LC3B, BECN1, NUP62, and TFEB were lower. By browsing into single-cell RNA sequencing datasets, we confirmed the high expression of CTSB in both COPD- and control-derived lung cells, whereas the other genes appeared less expressed (Supplementary Figure 1). Strikingly, CTSD resulted almost no expressed in single-cell data.

#### 3.3 Immunohistochemistry of autophagic molecules in bronchial biopsies

No differences in the expression of LAMP1, LC3A, p62, TFEB, Beclin-1 and cathepsin B/D were found in the bronchial epithelium of COPD patients compared to CNS and CS, but some differences

1  
2 226 emerged for LC3B (Table 3). Specifically, the number of LC3B positive cells was significantly lower  
3  
4 227 in the bronchial epithelium of non-smokers than in CS ( $p=0.04$ ) and in patients with severe/very  
5  
6 228 severe COPD ( $p=0.01$ ). The level of LC3B positive cells in patients with severe/very severe COPD  
7  
8  
9 229 was also significantly higher than in patients with mild/moderate disease ( $p=0.03$ ). The number of  
10  
11 230 cells positive for LAMP1, LC3A, LC3B, TFEB, Beclin-1, p62 and cathepsin B/D were similar in the  
12  
13 231 bronchial lamina propria of COPD patients of different severity compared to CNS and CS (Table 3).  
14  
15  
16 232 No significant association emerged between the expression levels of autophagic molecules in  
17  
18 233 bronchial biopsies and smoking history or respiratory function.  
19  
20

#### 21 234 *3.4 Immunohistochemistry of autophagic molecules in peripheral airways and lung parenchyma*

22  
23  
24 235 As shown in Table 4, no differences in the expression of LC3B, p62, TFEB, Beclin-1 and cathepsin  
25  
26 236 B/D were found in the bronchiolar epithelium of peripheral airways of COPD patients compared to  
27  
28  
29 237 CNS and CS. In comparison to CS and COPD patients, CNS expressed significantly lower levels of  
30  
31 238 LC3A ( $p<0.01$  and  $p<0.05$ , respectively) (Figure 2a,b), total LC3 ( $p<0.01$ ) and LAMP1 ( $p<0.01$ )  
32  
33 239 (Figure 2c,d). Similar results were found also in the analysis of alveolar macrophages and alveolar  
34  
35  
36 240 septa (Table 4). Specifically, alveolar macrophages of CS and COPD patients expressed higher levels  
37  
38 241 of LC3A ( $p<0.01$ ) and total LC3 ( $p<0.01$ ) in comparison to CNS. A higher level of LAMP1 was  
39  
40 242 found in CS in comparison to CNS ( $p<0.01$ ) but not to COPD patients. Concerning alveolar septa,  
41  
42  
43 243 CNS expressed lower levels of LC3A ( $p<0.01$ ) (Figure 2a,b), total LC3 ( $p<0.01$ ) and LAMP1  
44  
45 244 ( $p<0.01$ ) in comparison to both CS and COPD patients (Table 4). Importantly, CNS showed also a  
46  
47 245 lower number of p62 immunostained alveolar macrophages in comparison to CS and COPD patients  
48  
49 246 ( $p<0.01$  and  $p<0.05$ , respectively) (Table 4, Figure 3a,b). Double staining for LC3B (brown colour)  
50  
51  
52 247 and p62 protein (red colour), performed in 3 COPD patients and 3 CNS, showed a clear p62  
53  
54 248 immunoexpression in a large number of alveolar macrophages coexpressing LC3B in COPD lungs  
55  
56 249 (Figure 3c). On the other hand, the number of cathepsin B positive cell in alveolar septa was slightly  
57  
58  
59  
60

1  
2 250 but significantly higher in CNS than in the other two groups ( $p < 0.05$ ). Finally, the level of LC3B was  
3  
4 251 higher in the alveolar septa of CNS than in CS ( $p < 0.05$ ). No significant association emerged between  
5  
6  
7 252 the expression levels of autophagic molecules and smoking history or respiratory function.  
8

### 9 10 253 *3.5 ELISA tests for autophagic molecules in homogenized peripheral lung tissue*

11  
12  
13 254 As shown in Table 5 and Figure 4, we found no differences in the concentration of LAMP1 and LC3A  
14  
15 255 in the lung tissue homogenates of the 3 groups. CNS showed a reduced level of LC3B in comparison  
16  
17 256 to CS and COPD patients ( $p = 0.02$ ). Importantly, patients with COPD were found to have a higher  
18  
19  
20 257 level of p62 protein than CNS and CS ( $p = 0.02$ ), confirming data obtained by immunohistochemistry,  
21  
22 258 particularly in alveolar macrophages.  
23

## 24 25 259 **4. Discussion**

26  
27 260 With this study, we sought to evaluate through multiple techniques the autophagic process in COPD  
28  
29  
30 261 patients in different areas of the respiratory tract, comparing it with that of healthy subjects with or  
31  
32 262 without smoking history.  
33

34 263 Our data point out that autophagy is more stimulated in smokers than in non-smokers, regardless of  
35  
36 264 the presence of COPD. We found this stimulation in the bronchial mucosa as well as in small airways  
37  
38  
39 265 and lung parenchyma. As for the bronchial mucosa, this process was highlighted by an increase in  
40  
41 266 LC3B-positive cells in smoking controls and severe/very severe COPD patients compared with non-  
42  
43 267 smokers. In peripheral airways and lung parenchyma, on the other hand, stimulation of the autophagic  
44  
45  
46 268 process in smokers was indicated by increased LC3A, total LC3 and LAMP1 in bronchiolar  
47  
48 269 epithelium, alveolar septa and alveolar macrophages. ELISA tests performed on lung tissue  
49  
50 270 homogenate confirmed these data, showing a higher concentration of LC3B in both COPD patients  
51  
52  
53 271 and smoking subjects compared with CNS. Taken together, these findings strongly confirm previous  
54  
55 272 data and point out that autophagy represents a response to smoke exposure [4,25,29,30]. Of note, the  
56  
57  
58  
59  
60

1  
2 273 increase in LAMP1 together with LC3 supports a real boost in autophagic flux and confirms the  
3  
4 274 proper functioning of the lysosomal system [4,5,29,30].  
5

6 275 Intriguingly, the increase in autophagy seems to be independent of lung function deterioration, as it  
7  
8  
9 276 was evident – and comparable – in both CS and COPD patients. However, an impaired autophagic  
10  
11 277 flux emerged in patients with COPD when compared with controls. This difference was only  
12  
13 278 highlighted by ELISA test as an increased concentration in p62 level in the lung tissue homogenate  
14  
15  
16 279 and in alveolar macrophages by immunohistochemistry. The increase of p62 in lung tissue of patients  
17  
18 280 with COPD has been reported previously and has been interpreted as a potential mechanism of  
19  
20 281 impaired autophagy and proteostasis dysfunction, leading to COPD-emphysema development  
21  
22  
23 282 [15,25,31-33]. Indeed, this autophagy defect, induced by cigarette smoke but not present in smokers  
24  
25 283 with a normal lung function, could play a proapoptotic function and underlie the loss of peripheral  
26  
27 284 lung tissue, which is a feature of pulmonary emphysema [31-34]. Our data further support these  
28  
29  
30 285 hypotheses. The absence of differences in LAMP1 concentration, despite the increase in LC3B, also  
31  
32 286 suggests an impairment in the lysosomal system.  
33  
34

35 287 On the other hand, transcriptomics analyses conducted on both bronchial tissue and lung parenchyma  
36  
37 288 showed no significant differences in the expression of the mRNAs studied among the three groups.  
38  
39  
40 289 Supporting these results is the lack of differences in immunohistochemical analysis of TFEB,  
41  
42 290 considered a tool for monitoring transcriptional regulation connected with autophagy [5]. This lack  
43  
44 291 of differences might suggest that both stimulation and impairment of autophagic flux are primarily  
45  
46  
47 292 post-transcriptional, but further studies are needed to confirm these findings.  
48

49  
50 293 Also of note, the increased positivity of alveolar macrophages for p62, is able to differentiates  
51  
52 294 smokers, both COPD and control subjects, from non-smokers. This finding confirms the results  
53  
54 295 obtained by Monick *et al.* in a previous study [31]. Their data indicated an altered autophagic process  
55  
56  
57 296 at the level of alveolar macrophages, induced by a defect in the delivery of autophagosomes to the  
58  
59  
60

1  
2 297 lysosome. However, as in our study, this defect was associated with an increased stimulus for  
3  
4 298 autophagy, which they highlighted by an increased number of autophagosomes in smoking patients  
5  
6  
7 299 compared with controls. This could be explained by an increased macrophage loading of poorly  
8  
9 300 digestible material, which may lead to a defect in autophagy/lysosomal function [35]. This finding  
10  
11 301 seems particularly interesting because impairment of autophagy in alveolar macrophages could also  
12  
13 302 impair xenophagy, the autophagy involved in pathogen clearance [36]. As highlighted in previous  
14  
15 303 studies, impairment of xenophagy in macrophages could be one of the factors that explain the  
16  
17  
18 304 increased incidence of respiratory infections in smokers [31,37], regardless of respiratory function.  
19

20 305 Our results can be analysed in light of other studies where bronchial epithelial cells were stimulated  
21  
22 306 with cigarette smoke [18,25,30]. In these studies, stimulation with cigarette smoke led to activation  
23  
24  
25 307 of autophagy followed by accumulation of p62 and ubiquitinated proteins, which was interpreted as  
26  
27 308 impairment of the process and a precursor to cellular senescence [15]. Therefore, it can be  
28  
29  
30 309 hypothesized that different stimuli are capable of activating autophagy in HBECs (inflammation,  
31  
32 310 smoking exposure), but that only cigarette smoke is capable of leading to an impairment of the  
33  
34 311 autophagic process with accumulation of p62 and ubiquitinated proteins, precursor of cellular  
35  
36 312 senescence. Indeed, it has been proposed that the increased baseline autophagy found in patients with  
37  
38  
39 313 COPD is mainly due to oxidative stress and results in a reduced reserve of autophagy flux activation  
40  
41 314 in the bronchial epithelial cells of these patients. Confirming this, a significant decrease in autophagy  
42  
43 315 induction in response to cigarette smoke exposure was found in bronchial epithelial cells isolated  
44  
45  
46 316 from COPD patients when compared to those from non-smokers [15].  
47

48  
49 317 This study has some strengths and limitations. The main strength is the use of multiple methods  
50  
51 318 simultaneously to reinforce the results obtained at protein level quantitation, and to study different  
52  
53 319 stages of the autophagic process. Another strength is the analysis of these elements at different levels  
54  
55  
56 320 of the respiratory system including different cell types, so that a more complete view of an extremely  
57  
58  
59  
60

1  
2 321 complex system can be obtained. In contrast, one of the main limitations of the study is the absence  
3  
4 322 of in vitro tests, dedicated to specific mechanistic actions, which could have further strengthened our  
5  
6 323 findings. Another limitation is the use of archival material, which sometimes did not allow a more  
7  
8  
9 324 detailed analysis or an equal distribution of the population within the groups for certain variables,  
10  
11 325 such as gender, inhaled therapy and time since smoking cessation.  
12  
13

14 326 In conclusion, our study confirms by multiple techniques, all focused on mRNA and protein  
15  
16 327 quantitation, that cigarette smoke stimulates autophagy in different manners inside the respiratory  
17  
18  
19 328 system. The increase in the autophagic flux seems to be independent of lung function deterioration,  
20  
21 329 but an impairment of the process emerged in COPD patients. A reduced reserve of autophagy flux  
22  
23 330 activation due to oxidative stress may be one of the factors differentiating smokers with normal lung  
24  
25  
26 331 function from COPD patients, but this hypothesis needs to be confirmed. The same process could  
27  
28 332 make smokers more prone to respiratory infections due to xenophagy impairment in alveolar  
29  
30 333 macrophages. Both stimulation of autophagy and its deficiency appear primarily post-transcriptional,  
31  
32  
33 334 but further studies are needed to confirm these findings.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 335 **Tables**

3 336  
4 337  
5 338 **Table 1.** Clinical characteristics of subjects for immunohistochemistry studies on the bronchial  
6 339 biopsies  
7 340

8 340  
9  
10  
11  
12  
13  
14  
15  
16  
17

Groups	n	Age (y)	M/F	Ex/current smokers	Pack years	FEV <sub>1</sub> (% pred) pre-β <sub>2</sub>	FEV <sub>1</sub> (% pred) post-β <sub>2</sub>	FEV <sub>1</sub> /FVC (%)
Control non-smokers	12	63±13	8/4	0	0	117±18	ND	86±10
Control smokers	13	60±11	11/2	1/12	41±31	101±14	ND	81±6
COPD grades I and II (mild/moderate)	16	72±6	11/5	7/9	50±29	63±11 <sup>#</sup>	67±14	57±10 <sup>#</sup>
COPD grades III and IV (severe/very severe)	14	68±18	13/1	11/3	61±44	38±5 <sup>#&amp;</sup>	42±7	43±10 <sup>#&amp;</sup>

18 341  
19 342 Data are expressed as mean ± standard deviation. Patients with COPD were classified according to  
20 343 the grades of severity of the Global Initiative for Chronic Obstructive Lung Disease 2011  
21 344 (goldcopd.org) using only the severity of airflow obstruction. For patients with COPD, FEV<sub>1</sub>/FVC  
22 345 (%) are post-bronchodilator (β<sub>2</sub>) values. Abbreviations: COPD, chronic obstructive pulmonary  
23 346 disease; M, male; F, female, FEV<sub>1</sub>, forced expiratory volume in one second; FVC, forced vital  
24 347 capacity; ND, not determined. Statistical analysis: ANOVA test: #, p<0.0001, significantly different  
25 348 from control smokers with normal lung function and control never smokers; &, p<0.0001,  
26 349 significantly different from mild/moderate COPD.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 350  
3 351  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13 352  
14 353  
15 354  
16 355  
17 355  
18 356  
19 357  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2.** Clinical characteristics of subjects for immunohistochemistry studies on the peripheral lung tissue

Groups	n	Age (y)	M/F	Ex/Current smokers	Pack years	FEV <sub>1</sub> (% pred) pre-β <sub>2</sub>	FEV <sub>1</sub> (% pred) post-β <sub>2</sub>	FEV <sub>1</sub> /FVC (%)
<b>Control non-smokers</b>	11	71±10	5/6	---	---	115±15	ND	80±5
<b>Control smokers</b>	11	67±6	7/4	7/4	36±14	96±10	ND	74±4
<b>Patients with COPD</b>	12	69±6	11/1	10/2	51±39	72±16 <sup>#</sup>	79±14	59±9 <sup>#</sup>

Data are expressed as mean ± standard deviation. For patients with COPD, FEV<sub>1</sub>/FVC (%) are post-bronchodilator (β<sub>2</sub>) values. Abbreviations: COPD, chronic obstructive pulmonary disease; M, male; F, female; FEV<sub>1</sub>, forced expiratory volume in one second; FVC, forced vital capacity; ND, not determined. Statistical analysis: ANOVA test: #, p<0.0001, significantly different from control smokers with normal lung function and control never smokers.

For Review Only



**Table 3.** Immunohistochemistry of autophagic molecules in the bronchial biopsies of patients with COPD and control subjects.

Localization	Control non smokers N=12	Control smokers N=13	Mild/Moderate COPD N=16	Severe/very severe COPD N=14	Kruskal Wallis (p value)
<b>Epithelium</b>					
<b>Score (0-3)</b>					
<b>LC3A</b>	0.25 (0.25-0.5)	0 (0-0.75)	0.5 (0-1)	0.25 (0-1)	0.066
<b>LC3B</b>	1.5 (0.5-3)	2.5 (1.5-2.5)§	1.75 (1-2.5)	2.5 (1.5-3)*&	<b>0.020</b>
<b>TFEB total</b>	0.0 (0.0-0.5)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.925
<b>Cathepsin B</b>	0 (0-0)	0 (0-0)	0 (0-0)	0 (0-0)	ND
<b>Cathepsin D</b>	0.87 (0.75-1.25)	1 (0.5-1.5)	1.5 (0.75-2)	1.37 (0.75-1.5)	0.131
<b>Beclin-1</b>	1.5 (1.5-1.5)	1.5 (1-2)	1.5 (1.5-2)	1.5 (1.5-2.5)	0.742
<b>P62</b>	0.37 (0-0.5)	0.75(0.25-1.5)	0.5(0.25-1)	0.5(0.25-1)	0.359
<b>LAMP1</b>	1.0(0.5-1.5)	0.75(0.25-1)	0.75(0.25-1.5)	0.75(0.5-1)	0.377
<b>Lamina propria cells/mm<sup>2</sup></b>					
<b>LC3A</b>	8 (0-13)	4 (0-26)	9.5 (0-55)	13 (0-24)	0.373
<b>LC3B</b>	70 (32-200)	69 (21-97)	78 (16-118)	71 (29-156)	0.794
<b>TFEB total</b>	0.0 (0.0-34.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.953
<b>Cathepsin B</b>	4 (0-8)	5 (0-13)	0 (0-24)	0 (0-32)	0.494
<b>Cathepsin D</b>	12.5 (8-48)	47.5 (9-97)	41.5 (11-64)	38 (12-97)	0.256
<b>Beclin-1</b>	39 (9-81)	19.5 (0-92)	42 (0-87)	11 (5-124)	0.729
<b>P62</b>	32(5-74)	35(16-118)	13(0-56)	20(0-90)	0.098
<b>LAMP1</b>	216(142-322)	200(165-226)	208(78-274)	193(134-240)	0.564

Data are expressed as median and range. Abbreviations: COPD, chronic obstructive pulmonary disease; LC3, microtubule-associated protein 1A/1B-light chain 3; TFEB, transcription factor EB; LAMP1, lysosome-associated membrane protein 1; ND, not determined. Statistical analysis: Mann Whitney U test: \*, p=0.028 vs mild/moderate COPD; &, p=0.014 vs control non-smokers; §, p=0.0423 vs control non-smokers.

1

2 365

3 366

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

**Table 4.** Immunohistochemical quantification of autophagic molecules in the peripheral lung of patients with COPD, in control smokers and non-smoking subjects

Localization	Control non-smokers N=11	Control smokers N=11	Patients with COPD N=12	Kruskal Wallis (p value)
<b>Bronchiolar epithelium (score 0-3)</b>				
LC3A	0.40 (0.25-1.0)	1.50 (0.75-2.0)&	1.25 (0.5-2.0)*	<b>0.0013</b>
LC3B	2.50 (1.9-2.75)	2.75 (2.0-3.0)	2.75 (2.5-3.0)	0.287
LC3 (A+B)	2.75 (2.15-3.75)	3.95 (2.75-4.75) &	4 (3.24-4.5) &	<b>0.028</b>
TFEB total	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	ND
Cathepsin B	0.12 (0-0.50)	0.0 (0.0-0.50)	0.0 (0.0-0.12)	0.218
Cathepsin D	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	ND
Beclin-1	2.32 (2.0-2.5)	2.50 (1.5-2.75)	2.5 (1.5-2.75)	0.214
P62	0.0 (0.0-0.0)	0.0 (0.0-0.12)	0.0 (0.0-0.0)	0.715
LAMP1	0.12 (0.0-0.25)	1.0 (0.37-1.50)&	0.55 (0.5-0.75)&	<b>&lt;0.0001</b>
<b>Alveolar macrophages (score 0-3)</b>				
LC3A	0.5 (0.25-1.0)	1.5 (1.0-2.0)&	1.25 (1.0-1.25)&	<b>0.0001</b>
LC3B	2.0 (1.5-2.5)	2.0 (1.75-2.5)	2.0 (2-2.5)	0.237
LC3 (A+B)	2.5 (1.75-3)	3.5 (3-4.5) &	3.25 (3-3.75) &	<b>0.0004</b>
TFEB total	0.0 (0.0-1.4)	0.05 (0.0-1.6)	0.0 (0.0-1.5)	0.7342
TFEB nuclear	0.0 (0.0-0.35)	0.0 (0.0-0.27)	0.0 (0.0-0.24)	0.6924
TFEB cytoplasmic	0.0 (0.0-1.05)	0.05 (0.0-1.5)	0.0 (0.0-1.5)	0.7260
Cathepsin B	0.12 (0.12-0.75)	0.50 (0.0-1.75)	0.31 (0.12-1.5)	0.640
Cathepsin D	0.0 (0.0-0.25)	0.0 (0.0-0.50)	0.10 (0.0-0.50)	0.980
Beclin-1	1.5 (1.25-2.0)	1.75 (1.25-2.0)	1.62 (1.25-2.0)	0.272
P62	0.0 (0.0-0.12)	0.50 (0.5-1.0)&	0.50 (0.0-1.0)*	<b>0.0009</b>
LAMP1	1.5 (0.75-2.0)	2.0 (1.5-2.5)&	1.5 (1.5-2.0)	<b>0.021</b>
<b>Alveolar septa (score 0-3)</b>				
LC3A	0.0 (0.0-0.5)	1.0 (0.75-1.25)&	1.0 (1.0-1.0)&	<b>&lt;0.0001</b>
LC3B	2.0 (1.5-2.5)	1.75 (1.5-2.0)*	2.0 (1.75-2.0)	<b>0.022</b>
LC3 (A+B)	2.5 (1.5-2.5)	3 (2.25-3) &	3 (2.75-3) &	<b>0.0007</b>
TFEB total	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	ND
Cathepsin B	0.12 (0.0-0.50)	0.0 (0.0-0.12)*	0.0 (0.0-0.5)*	<b>0.041</b>
Cathepsin D	0. (0.0-0.12)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.890
Beclin-1	1.5 (1.25-2.0)	1.5 (1.25-2.0)	1.62 (1.5-1.75)	0.722
P62	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	ND

<b>LAMP1</b>	0.75 (0.25-1.0)	1.0 (1.0-1.5)&	1.0 (1.0-1.0)&	<b>0.0021</b>
--------------	-----------------	----------------	----------------	---------------

Data are expressed as median and range. Abbreviations: COPD, chronic obstructive pulmonary disease; LC3, microtubule-associated protein 1A/1B-light chain 3; TFEB, transcription factor EB; LAMP1, lysosome-associated membrane protein 1; ND, not determined. Statistical analysis: ; Mann Whitney U test: \*,  $p < 0.05$  vs control non-smokers; &,  $p < 0.01$  vs control non-smokers.

For Review Only

1

2 371 **Table 5.** ELISA tests for autophagic molecules in the lung parenchyma of control non-smokers,  
 3 372 control smokers and patients with COPD.

Proteins	Control non-smokers N=11	Control smokers N=11	Patients with COPD N=10	Kruskal Wallis (p value)
LC3A (ng/mL)	334 (188.5-835.5)	438 (25.50-700)	405.5 (63.50-1048)	0.9976
LC3B (ng/mL)	720 (405-1105)	1235 (545-1985)*	1200 (490-3625)*	<b>0.0230</b>
LC3A+LC3B (ng/ml)	1184 (820-1520)	1586 (816-2564)*	1768 (716-4470)*	<b>0.0333</b>
LAMP1 (ng/mL)	679 (223-2752)	966.5 (230.5-2687)	705.5 (179-4352)	0.5941
P62 (ng/mL)	0 (0.00-15.85)	0 (0.00-18.55)	12.15 (0.00-33.45)*&	<b>0.0231</b>

20 373 Data are expressed as median and range. Abbreviations: COPD, chronic obstructive pulmonary  
 21 374 disease; LC3, microtubule-associated protein 1A/1B-light chain 3; LAMP1, lysosome-associated  
 22 375 membrane protein 1. Statistical analysis: ; Mann Whitney U test: \*, p<0.05 vs control non-smokers;  
 23 376 &, p<0.05 vs control smokers.

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

60

60

60

60

60

60

60

60

60

60

## References

1. Mizushima N, Komatsu M. Autophagy: Renovation of cells and tissues. *Cell* 2011; 147: 728–741.
2. Barnes PJ, Baker J, Donnelly LE. Autophagy in asthma and chronic obstructive pulmonary disease. *Clin. Sci.* 2022; 136: 733–746.
3. Zeng X, Overmeyer JH, Maltese WA. Functional specificity of the mammalian Beclin-Vps34 PI 3-kinase complex in macroautophagy versus endocytosis and lysosomal enzyme trafficking. *J. Cell Sci.* 2006; 119: 259–270.
4. Bonam SR, Bayry J, Tschan MP, *et al.* Progress and Challenges in The Use of MAP1LC3 as a Legitimate Marker for Measuring Dynamic Autophagy In Vivo. *Cells* 2020; 9: 1321.
5. Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, *et al.* Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)<sup>1</sup>. *Autophagy* 2021; 17: 1–382.
6. Chen Y, Li Q, Li Q, *et al.* p62/SQSTM1, a Central but Unexploited Target: Advances in Its Physiological/Pathogenic Functions and Small Molecular Modulators. *J. Med. Chem.* 2020; 63: 10135–10157.
7. Levine B, Kroemer G. Autophagy in the Pathogenesis of Disease. *Cell* 2008; 132: 27–42.
8. Zhao X, Zhang Q, Zheng R. The interplay between oxidative stress and autophagy in chronic obstructive pulmonary disease. *Front. Physiol.* 2022; 13: 1–15.
9. Di Stefano A, Gnemmi I, Dossena F, *et al.* Pathogenesis of COPD at the cellular and molecular level. *Minerva Med.* 2022; 113: 405–423.
10. Agusti A, Celli BR, Criner GJ, *et al.* Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. *ERJ* 2023; 61 (4): 2300239.
11. Fujita Y, Araya J, Ito S, *et al.* Suppression of autophagy by extracellular vesicles promotes myofibroblast differentiation in COPD pathogenesis. *J. Extracell. Vesicles* 2015; 4: 28388.
12. Jati S, Kundu S, Chakraborty A, *et al.* Wnt5A signaling promotes defense against bacterial pathogens by activating a host autophagy circuit. *Front. Immunol.* 2018; 9: 679.
13. Kuwano K, Araya J, Hara H, *et al.* Cellular senescence and autophagy in the pathogenesis of chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). *Respir. Investig.* 2016; 54: 397–406.
14. Jiang S, Sun J, Mohammadtursun N, *et al.* Dual role of autophagy/mitophagy in chronic obstructive pulmonary disease. *Pulm. Pharmacol. Ther.* 2019; 56: 116–125.
15. Fujii S, Hara H, Araya J, *et al.* Insufficient autophagy promotes bronchial epithelial cell senescence in chronic obstructive pulmonary disease. *Oncoimmunology* 2012; 1: 630–641.
16. Mizumura K, Maruoka S, Shimizu T, *et al.* Autophagy, selective autophagy, and necroptosis in COPD. *Int. J. COPD* 2018; 13: 3165–3172.
17. Lam HC, Cloonam SM, Bhashyam AR, *et al.* Histone deacetylase 6-mediated selective autophagy regulates copd-associated cilia dysfunction. *J. Clin. Invest.* 2013; 123: 5212–5230.
18. Li Y, Yu G, Yuan S, *et al.* 14,15-Epoxyeicosatrienoic acid suppresses cigarette smoke condensate-induced inflammation in lung epithelial cells by inhibiting autophagy. *Am. J. Physiol. - Lung Cell. Mol. Physiol.* 2016; 311: L970–L980.
19. Wang Y, Liu J, Zhou J, *et al.* MTOR Suppresses Cigarette Smoke-Induced Epithelial Cell Death and Airway Inflammation in Chronic Obstructive Pulmonary Disease. *J. Immunol.* 2018; 200: 2571–2580.
20. Zhou JS, Zhao Y, Zhou HB, *et al.* Autophagy plays an essential role in cigarette smoke-induced expression of MUC5AC in airway epithelium. *Am. J. Physiol. - Lung Cell. Mol. Physiol.* 2016; 310: L1042–L1052.
21. Bialik S, Dasari SK, Kimchi A. Autophagy-dependent cell death - where, how and why a

- 1  
2 425 cell eats itself to death. *J. Cell Sci.* 2018; 131: jcs215152.
- 3 426 22. Gouzi F, Blaquièrre M, Catteau M, et al. Oxidative stress regulates autophagy in cultured  
4 427 muscle cells of patients with chronic obstructive pulmonary disease. *J. Cell. Physiol.* 2018;  
5 428 233: 9629–9639.
- 6 429 23. Guo Y, Gosker HR, Schols AMWJ, et al. Autophagy in locomotor muscles of patients with  
7 430 chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* 2013; 188: 1313–  
8 431 1320.
- 9 432 24. Tan WSD, Shen HM, Wong WSF. Dysregulated autophagy in COPD: A pathogenic process  
10 433 to be deciphered. *Pharmacol. Res.* 2019; 144: 1–7.
- 11 434 25. Vij N, Chandramani-Shivalingappa P, Van Westphal C, et al. Cigarette smoke-induced  
12 435 autophagy impairment accelerates lung aging, copd-emphysema exacerbations and  
13 436 pathogenesis. *Am. J. Physiol. - Cell Physiol.* 2018; 314: C73–C87.
- 14 437 26. Bodas M, Vij N. Augmenting autophagy for prognosis based intervention of COPD-  
15 438 pathophysiology. *Respir. Res.* 2017; 18: 1–8.
- 16 439 27. Di Stefano A, Caramori G, Barczyk A, et al. Innate immunity but not NLRP3  
17 440 inflammasome activation correlates with severity of stable COPD. *Thorax* 2014; 69: 516–  
18 441 524.
- 19 442 28. Sauler M, McDonough JE, Adams TS, et al. Characterization of the COPD alveolar niche  
20 443 using single-cell RNA sequencing. *Nat. Commun.* 2022; 13: 494.
- 21 444 29. Bartlett BJ, Isakson P, Lewerenz J, et al. p62, Ref(2)P and ubiquitinated proteins are  
22 445 conserved markers of neuronal aging, aggregate formation and progressive autophagic  
23 446 defects. *Autophagy* 2011; 7: 572–583.
- 24 447 30. Chen ZH, Kim HP, Scirba FC, et al. Egr-1 regulates autophagy in cigarette smoke-induced  
25 448 chronic obstructive pulmonary disease. *PLoS One* 2008; 3(10): e3316.
- 26 449 31. Monick MM, Powers LS, Walters K, et al. Identification of an Autophagy Defect in  
27 450 Smokers' Alveolar Macrophages. *J. Immunol.* 2010; 185: 5425–5435.
- 28 451 32. Tran I, Ji C, Ni I, et al. Role of cigarette smoke-induced aggresome formation in chronic  
29 452 obstructive pulmonary disease-emphysema pathogenesis. *Am. J. Respir. Cell Mol. Biol.*  
30 453 2015; 53: 159–173.
- 31 454 33. Mercado N, Colley T, Baker JR, et al. Bicaudal D1 impairs autophagosome maturation in  
32 455 chronic obstructive pulmonary disease. *FASEB BioAdvances* 2019; 1: 688–705.
- 33 456 34. Hong PK, Wang X, Chen ZH, et al. Autophagic proteins regulate cigarette smoke-induced  
34 457 apoptosis: Protective role of heme oxygenase-1. *Autophagy* 2008; 4: 887–895.
- 35 458 35. Montgomery RR, Webster P, Mellman I. Accumulation of indigestible substances reduces  
36 459 fusion competence of macrophage lysosomes. *J. Immunol.* 1991; 147: 3087–3095.
- 37 460 36. Levine B. Eating oneself and uninvited guests: Autophagy-related pathways in cellular  
38 461 defense. *Cell* 2005; 120: 159–162.
- 39 462 37. Zheng YT, Shahnazari S, Brech A, et al. The Adaptor Protein p62/SQSTM1 Targets  
40 463 Invading Bacteria to the Autophagy Pathway. *J. Immunol.* 2009; 183: 5909–5916.
- 41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 469 **Figure legends**

3 470  
4  
5 471 **Figure 1**

6  
7  
8 472 Expression levels of selected autophagy genes obtained in bronchial rings (a) and lung parenchyma  
9  
10 473 (b) of control non-smokers (CNS), control smokers (CS) patients with chronic obstructive pulmonary  
11  
12 474 disease (COPD). The box plot showed the median and the distribution of expression values per gene.  
13  
14  
15 475 Abbreviations: TEFB, Transcription Factor EB; CTSB, Cathepsin B; CTSD, Cathepsin D; LAMP1,  
16  
17 476 Lysosomal-associated membrane protein 1; MAP1LC3B, Microtubule Associated Protein 1 Light  
18  
19 477 Chain 3 Beta; BECN1, Beclin 1; NUP62, Nucleoporin 62; MAP1LC3B, Microtubule Associated  
20  
21  
22 478 Protein 1 Light Chain 3 Alpha.  
23

24 479  
25  
26 480 **Figure 2**

27  
28 481 Photomicrographs showing bronchiolar epithelium, alveolar macrophages and alveolar septa of  
29  
30 482 control non-smokers (a,c) and COPD patients (b,d) immunostained for identification of LC3A (a,b)  
31  
32 483 and LAMP1 (c,d). Results for single stainings are representative of those from 11 non-smokers and  
33  
34 484 12 mild/moderate COPD patients. An increased immunopositivity for LC3A and for LAMP1 was  
35  
36 485 observed in bronchiolar epithelium (BE), alveolar macrophages (arrows) and alveolar septa  
37  
38 486 (arrows) in COPD patients. CNS=Control Non Smokers, COPD=Chronic Obstructive Pulmonary  
39  
40 487 Disease; Bars=30  $\mu$ m.  
41  
42  
43  
44  
45 488

46  
47 489 **Figure 3**

48  
49 490 Photomicrographs showing alveolar macrophages and alveolar septa (a,b) of control non-smokers (a)  
50  
51 491 and COPD patients (b) immunostained for identification of p62 (a,b). Panel c shows double stained  
52  
53 492 macrophages from a patient with COPD showing immunopositivity for p62 (red colour) and LC3B  
54  
55 493 (brown colour), the most expressed autophagy marker in alveolar macrophages. Results for single  
56  
57  
58  
59  
60

1  
2 494 staining are representative of those from 11 non-smokers and 12 mild/moderate COPD patients.  
3  
4 495 Double staining was performed in 3 control non-smokers and in 3 patients with COPD. Arrows  
5  
6 496 indicate single or double-immunostained alveolar macrophages. An increased immunopositivity for  
7  
8  
9 497 p62 antigen is shown in COPD patients compared to control non-smokers. Bars=30 microns (a,b) and  
10  
11 498 15 microns (c).

12  
13 49914  
15  
16 500 **Figure 4**

17  
18 501 Quantitation by ELISA tests of LC3A (a), LC3B (b), LC3A+LC3B (c), LAMP1 (d) and p62 (e)  
19  
20 502 molecules in the lung protein extracts of control non-smokers (CNS, n=11), control smokers (CS,  
21  
22 n=11) and patients with chronic obstructive pulmonary disease (COPD, n=12). LC3B and  
23 503 LC3A+LC3B showed higher values in COPD and CS compared to CNS (b,c). P62 was increased in  
24  
25 504 COPD patients compared to CS and CNS (e). Data are expressed as mean  $\pm$  standard errors. Mann  
26  
27 505 Whitney was used test for comparison between groups.  
28  
29  
30 506

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60






Figure 1

Expression levels of selected autophagy genes obtained in bronchial rings (a) and lung parenchyma (b) of control non-smokers (CNS), control smokers (CS) patients with chronic obstructive pulmonary disease (COPD). The box plot showed the median and the distribution of expression values per gene. Abbreviations: TFE3, Transcription Factor EB; CTSB, Cathepsin B; CTSD, Cathepsin D; LAMP1, Lysosomal-associated membrane protein 1; MAP1LC3B, Microtubule Associated Protein 1 Light Chain 3 Beta; BECN1, Beclin 1; NUP62, Nucleoporin 62; MAP1LC3A, Microtubule Associated Protein 1 Light Chain 3 Alpha.

50x30mm (600 x 600 DPI)




Figure 2

Photomicrographs showing bronchiolar epithelium, alveolar macrophages and alveolar septa of control non-smokers (a,c) and COPD patients (b,d) immunostained for identification of LC3A (a,b) and LAMP1 (c,d). Results for single stainings are representative of those from 11 non-smokers and 12 mild/moderate COPD patients. An increased immunopositivity for LC3A and for LAMP1 was observed in bronchiolar epithelium (BE), alveolar macrophages (arrows) and alveolar septa (arrows) in COPD patients. CNS=Control Non-Smokers, COPD=Chronic Obstructive Pulmonary Disease; Bars=30  $\mu$ m.

55x42mm (600 x 600 DPI)




Figure 3

Photomicrographs showing alveolar macrophages and alveolar septa (a,b) of control non-smokers (a) and COPD patients (b) immunostained for identification of p62 (a,b). Panel c shows double stained macrophages from a patient with COPD showing immunopositivity for p62 (red colour) and LC3B (brown colour), the most expressed autophagy marker in alveolar macrophages. Results for single staining are representative of those from 11 non-smokers and 12 mild/moderate COPD patients. Double staining was performed in 3 control non-smokers and in 3 patients with COPD. Arrows indicate single or double-immunostained alveolar macrophages. An increased immunopositivity for p62 antigen is shown in COPD patients compared to control non-smokers. Bars=30 microns (a,b) and 15 microns (c).

27x6mm (1200 x 1200 DPI)




Figure 4

Quantitation by ELISA tests of LC3A (a), LC3B (b), LC3A+LC3B (c), LAMP1 (d) and p62 (e) molecules in the lung protein extracts of control non-smokers (CNS, n=11), control smokers (CS, n=11) and patients with chronic obstructive pulmonary disease (COPD, n=12). LC3B and LC3A+LC3B showed higher values in COPD and CS compared to CNS (b,c). P62 was increased in COPD patients compared to CS and CNS (e). Data are expressed as mean  $\pm$  standard errors. Mann Whitney was used test for comparison between groups.

24x14mm (1200 x 1200 DPI)

**Impaired autophagy in the lower airways and lung parenchyma in stable COPD**

Stefano Levra MD<sup>1</sup>, Umberto Rosani PhD<sup>2</sup>, Isabella Gnemmi<sup>3</sup>, Paola Brun PhD<sup>4</sup>, Andrea Leonardi MD<sup>5</sup>, Vitina Carriero PhD<sup>1</sup>, Francesca Bertolini PhD<sup>1</sup>, Bruno Balbi MD<sup>6</sup>, Mirella Profita PhD<sup>7</sup>, Fabio Luigi Massimo Ricciardolo MD<sup>1,7,8\*</sup>, Antonino Di Stefano PhD<sup>3\*</sup>.

For Review Only

## Methods

### *Subjects*

All COPD patients and healthy control subjects were recruited from the Respiratory Medicine Unit of the “Istituti Clinici Scientifici Maugeri” (Veruno, Italy) and the Department of Clinical and Biological Sciences of the San Luigi Gonzaga University Hospital (Orbassano, Italy). Archival material was used in the present study [1]. We obtained bronchial biopsies from 55 subjects for the immunohistochemical study of bronchial tissue. Thirty-four subjects undergoing lung resection for a solitary peripheral neoplasm were recruited for the immunohistochemical study of peripheral lung tissue and transcriptomic analysis of bronchial rings and lung tissue. All COPD patients were stable and had not been treated with theophylline, antibiotics, antioxidants, mucolytics, and/or glucocorticoids in the month prior to bronchoscopy or lung resection surgery.

### *Lung function tests and volumes*

Pulmonary function tests included measurements of FEV<sub>1</sub> and FEV<sub>1</sub>/FVC under baseline conditions in all the subjects examined (6200 Autobox Pulmonary Function Laboratory; Sensormedics Corp., Yorba Linda, CA). In order to assess the reversibility of airflow obstruction and post bronchodilator functional values, the measurements in the groups of subjects with FEV<sub>1</sub>/FVC ≤ 70% were repeated 20 min after the inhalation of 0.4 mg of salbutamol.

### *Fibreoptic bronchoscopy, collection and processing of bronchial biopsies*

We obtained bronchial biopsies from 55 subjects for the immunohistochemical study of bronchial tissue, including 30 with COPD (Table 1 of the main manuscript). Subjects attended the bronchoscopy suite at 8.30 AM after having fasted from midnight and were pre-treated with atropine (0.6 mg IV) and midazolam (5-10 mg IV). Oxygen (3 l/min) was administered via nasal prongs throughout the procedure and oxygen saturation was monitored with a digital oximeter. After local

1 anaesthesia with lidocaine (4%) to the upper airways and larynx, a fiberoptic bronchoscope (Olympus  
2 BF10 Key-Med, Southend, UK) was passed into the trachea through the nose. Further lidocaine (2%)  
3  
4 was sprayed into the lower airways, and four bronchial biopsy specimens were taken from segmental  
5  
6 and subsegmental airways (4<sup>th</sup> to 6<sup>th</sup> airway generation) of the right lower and upper lobes using size  
7  
8 and subsegmental airways (4<sup>th</sup> to 6<sup>th</sup> airway generation) of the right lower and upper lobes using size  
9  
10 19 cupped forceps. Bronchial biopsies for immunohistochemistry were gently extracted from the  
11  
12 forceps and processed for light microscopy [1]. At least two samples were embedded in Tissue Tek  
13  
14 II OCT (Miles Scientific, Naperville, IL), frozen within 15 min in isopentane pre-cooled in liquid  
15  
16 nitrogen, and stored at  $-80^{\circ}\text{C}$ . The best frozen sample was then oriented and  $6\mu\text{m}$  thick cryostat  
17  
18 sections were cut for immunohistochemical light microscopy analysis and processed as described  
19  
20 below.  
21  
22  
23  
24  
25  
26

### 27 *Collection and processing of the peripheral lung tissue*

28  
29 Thirty-four subjects undergoing lung resection surgery for a solitary peripheral neoplasm were  
30  
31 recruited. Eleven were non-smokers with normal lung function, 11 were smokers with normal lung  
32  
33 function and 12 were smokers with COPD (Table 2 of the main manuscript). All former smokers had  
34  
35 stopped smoking for more than one year. All subjects did not undergo preoperative chemotherapy  
36  
37 and/or radiotherapy and had not been treated with bronchodilators, theophylline, antibiotics,  
38  
39 antioxidants and/or glucocorticoids in the month prior to surgery. Lung tissue processing was  
40  
41 performed as previously described [1]. Two to four randomly selected tissue blocks and one-two  
42  
43 bronchial rings were taken from the lung obtained at surgery, avoiding areas grossly invaded by  
44  
45 neoplasia. Samples were fixed in 4% formaldehyde in phosphate-buffered saline at pH 7.2 or frozen  
46  
47 in liquid nitrogen. Fixed specimens, after dehydration, were embedded in paraffin wax. Serial sections  
48  
49  $6\mu\text{m}$  thick from frozen specimens were first cut and stained with haematoxylin-eosin (H&E) in order  
50  
51 to visualize the morphology and to exclude the presence of microscopically evident tumour  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2 infiltration. Frozen tissue specimens were used in this study. Specimens were then cut for  
3  
4 immunohistochemical analysis and were placed on charged slides as previously reported [1].  
5  
6  
7

#### 8 9 *Immunohistochemistry on OCT-embedded bronchial biopsies*

10 Sections from each sample were stained with antibodies specific for autophagy markers and proteins  
11 (Table 1). Briefly, after blocking non-specific binding sites with serum derived from the same animal  
12  
13 (Table 1). Briefly, after blocking non-specific binding sites with serum derived from the same animal  
14  
15 species as the secondary antibody, the primary antibody was applied at optimal dilutions in TRIS-  
16  
17 buffered saline (0.15 M saline containing 0.05 M TRIS-hydrochloric acid at pH 7.6) and incubated  
18  
19 1hr at room temperature in a humid chamber. Antibody binding was detected with secondary anti-  
20  
21 mouse (Vector, BA 2000), anti-rabbit (Vector, BA 1000) antibodies followed by ABC kit AP  
22  
23 AK5000, Vectastain and fast-red substrate (red colour) or ABC kit HRP Elite, PK6100, Vectastain  
24  
25 and diaminobenzidine substrate (brown colour). Nasal polyp sections were used as positive controls.  
26  
27 For the negative control, normal mouse (sc-2025) or rabbit (sc-2027) non-specific immunoglobulins  
28  
29 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used at the same protein concentration as  
30  
31 the primary antibody.  
32  
33  
34  
35  
36  
37

#### 38 39 *Immunohistochemistry in peripheral lung tissue*

40 Immunostaining of frozen peripheral lung tissue was performed as previously described [1].  
41  
42 Endogenous peroxidase activity was blocked by incubating slides in 3% hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)  
43  
44 in phosphate-buffered saline (PBS) followed by washing in PBS. Cell membranes were permeabilized  
45  
46 adding 0.1% saponin to the PBS. Non-specific labelling was blocked by coating with blocking serum  
47  
48 (5% normal specie-specific serum) for 20 minutes at room temperature. After washing in PBS the  
49  
50 sections were incubated with anti-primary antibodies used for bronchial biopsies (Supplementary  
51  
52 table 1). Control slides were included in each staining run using human normal tonsils or nasal polyps  
53  
54 as a positive control for all the immunostaining performed. Slides were then incubated with  
55  
56  
57  
58  
59  
60



1  
2 chromogen-fast diaminobenzidine (DAB) as chromogenic substance. After which they were  
3  
4 counterstained in haematoxylin and mounted on permanent mounting medium. Double staining was  
5  
6 performed for identification of alveolar macrophages positively stained for LC3B (brown colour)  
7  
8 coexpressing also p62 (red colour) protein in three control non-smokers and in 3 patients with COPD.  
9  
10 Chromogens used were the fast-red (red colour) and DAB (brown colour) substrates for identification  
11  
12 of double marked alveolar macrophages.  
13  
14  
15  
16  
17

#### 18 *Scoring system for immunohistochemistry in the bronchial biopsies*

19  
20 Light-microscopic analysis was performed at a magnification of 630x. The immunostaining for all  
21  
22 the antigens studied was scored (range: 0 = absence of immunostaining to 3 = extensive intense  
23  
24 immunostaining) in the intact bronchial epithelium. The final result was expressed as the average of  
25  
26 all scored fields performed in each biopsy.  
27  
28

29 Immunostained cells in the bronchial lamina propria were quantified 100µm beneath the epithelial  
30  
31 basement membrane in several non-overlapping high-power fields until the whole specimen was  
32  
33 examined. The final result was expressed as the number of positive cells per square millimetre.  
34  
35  
36  
37  
38

#### 39 *Scoring system for immunohistochemistry in the peripheral lung tissue*

40  
41 All bronchioles, alveolar macrophages and alveolar septa observed in each lung section specimen  
42  
43 were analysed for each immunostained section. The immunopositivity was scored (0 = absence of  
44  
45 immunostaining, 1 = 33% of immunostained cells, 2 = 66% of immunostained cells, 3 = almost all  
46  
47 positive cells). Intensity of immunopositivity was considered adding a 0.5 score point to the  
48  
49 established score applied on the basis of number of positive cells in the bronchiolar epithelium,  
50  
51 bronchiolar lamina propria, alveolar macrophages, and alveolar septa [1].  
52  
53  
54  
55  
56

#### 57 *RNA extraction and sequencing from bronchial rings and peripheral lung specimens*

1  
2 Frozen lung parenchymal tissues used for immunohistochemical analysis and bronchial rings from  
3  
4 the same patients were also used for RNA extraction, sequencing and gene expression analysis. RNA  
5  
6 extraction was performed with the RNAeasy micro kit (Qiagen, Hilden, Germany) following  
7  
8 manufacturer instructions, with a DNA removal step using 500 units of RNase-free DNase (Qiagen)  
9  
10 at room temperature for 15 minutes. Total RNA was resuspended in RNase-free water (Thermo  
11  
12 Fisher, Carlsbad, US) and the RNA/DNA concentrations in each sample were quantified using the  
13  
14 Qubit RNA and DNA high-sensitivity Assay Kit (Thermo Fisher). RNA qualities were assessed with  
15  
16 an Agilent Bioanalyzer 2100 equipped with a RNA nano 6000 kit (Agilent, Santa Clara, CA, USA).  
17  
18 Due to the low RIN values obtained for lung parenchyma samples, RNA-sequencing libraries for  
19  
20 these samples were prepared following a 3'-end sequencing procedure using the QuantSeq 3' mRNA-  
21  
22 Seq Library Prep Kit FWD for Illumina (Lexogen, Vienna, Austria). Differently, no quality issues  
23  
24 were encountered for the bronchial ring samples and, therefore, standard Illumina library preparation  
25  
26 were performed. Consequently to the different library preparation methods, lung parenchyma libraries  
27  
28 were sequenced using an Illumina NextSeq500 with a 75 single end read layout, whereas bronchial  
29  
30 ring libraries were sequenced with a 150 paired-end read layout (Cribi, UniPD, Padova, Italy).  
31  
32  
33  
34  
35  
36  
37  
38

### 39 *Data analysis of RNA-seq data*

40  
41 The raw Illumina reads were trimmed for quality using *fastp* [2], setting a minimal Phred quality of  
42  
43 25 and removing the sequencing adaptors. Raw Illumina datasets have been submitted to the NCBI  
44  
45 Short Read Archive (SRA) under the project ID PRJNA80144. FASTQ files were imported in the  
46  
47 CLC Genomic Workbench v.21 (Qiagen, Hilden, Denmark) and analysed as follows. The trimmed  
48  
49 reads were mapped on the human reference genome (hg19, Ensembl v.99) applying the following  
50  
51 parameters: mismatch cost = 2; insertion cost = 3; deletion cost = 3; length fraction = 0.8; similarity  
52  
53 fraction = 0.8 and setting a strand-specific mapping. Expression values were counted as Read Per  
54  
55 Kilobase of Mapped reads (RPKM). To identify differentially expressed genes (DEGs), a Baggerley  
56  
57  
58  
59  
60

1  
2 test with false discovery rate (FDR) p-value correction was applied, setting a cut-off of a minimal 2-  
3  
4 Fold changes (FC) and a maximal 0.05 of FDR p-value. Limited to the gene of interest, MAP1LC3A,  
5  
6 MAP1LC3B, CTSB, CTSD, BECN1, NUP62, LAMP1 and TFEB, the expression levels were  
7  
8 extracted from the overall dataset and discussed (supplementary Table 2). The expression level of  
9  
10 these genes was also evaluated in <http://www.copdcellatlas.com/>, a COPD-dedicated gene expression  
11  
12 browser of single-cell RNA sequencing data [3].  
13  
14  
15

#### 16 *ELISA tests in the peripheral lung tissue homogenates*

17  
18  
19 LC3A (MyBioSource, Cat. N. MBS760439, lower detection limit, 0.156ng/ml), LC3B  
20  
21 (MyBioSource, Cat.N. MBS7254329, lower detection limit, 0.10 ng/ml), LAMP1 (MyBioSource,  
22  
23 Cat.N. MBS2023492, lower detection limit, 0.055 ng/ml) and p62 (MyBioSource, Cat.N.  
24  
25 MBS008191, lower detection limit, 0.10 ng/ml) proteins quantification was performed in the lung  
26  
27 tissue homogenates obtained from frozen tissue specimens used also for immunohistochemical  
28  
29 analysis. ELISA kits were used according to the manufacturer's instructions.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 **Figure legend**  
3  
4

5 **Supplementary Figure 1**  
6

7  
8 The figure depicts the expression levels of seven selected genes (BECN, CTSB, CTSD, LAMP1,  
9  
10 MAP1LC3A, MAP1LC3B and TFEB) in different cell types (epithelial, endothelial, stromal  
11  
12 and immune cells) of patients with COPD and control subjects obtained from the COPD Cell Atlas  
13  
14 (<http://www.copdcellatlas.com/>). The expression level is represented by a colour-scale, whereas the  
15  
16 fraction of the cells expressing the given gene is represented by the size of the dot.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Review Only

## Tables

**Supplementary Table 1.** Primary antibodies and immunohistochemical conditions used for identification of autophagic molecules and proteins in bronchial biopsies and lung parenchyma

Target	Supplier	Cat.# <sup>a</sup>	Source	Dilution	Positive Control
LC3A	LS Bio	LS-B7938	Rabbit	1:100	Nasal polyp
LC3B	Novus Bio	NB100-2220	Rabbit	1:1000	Nasal polyp
TFEB total	Santa Cruz	Sc-166736	Mouse	1:100	Nasal polyp
Cathepsin B	Santa Cruz	Sc-365558	Mouse	1:100	Nasal polyp
Cathepsin D	Santa Cruz	Sc-13148	Mouse	1:200	Nasal polyp
Beclin-1	Novus Bio	NB500-249	Rabbit	1:800	Nasal polyp
P62	Santa Cruz	Sc-28359	Mouse	1:100	Nasal polyp
LAMP1	Invitrogen	PA1-654A	Rabbit	1:20000	Nasal polyp

Abbreviations: LC3, microtubule-associated protein 1A/1B-light chain 3; TFEB, transcription factor EB; LAMP1, lysosome-associated membrane protein 1.

**Supplementary Table 2.** Transcriptomic data for autophagic molecules obtained in bronchial rings and lung parenchyma of COPD, control non-smokers and control smoker patients.


Gene ID	Gene description	COPD - Mean	CNS - Mean	CS - Mean	COPD - Mean	CNS - Mean	CS - Mean
		Bronchial rings			Lung parenchyma		
MAP1LC3A (LC3A)	Microtubule Associated Protein 1 Light Chain 3 Alpha	29.1	23.9	41.4	22.5	21.9	21.2
MAP1LC3B (LC3B)	Microtubule Associated Protein 1 Light Chain 3 Beta	33.9	23.6	35.3	92.1	106.8	97.2
CTSB	Cathepsin B	216.2	144.8	281.9	852.9	690.4	748.0
CTSD	Cathepsin D	519.5	338.4	723.5	1685.3	1425.3	1613.3
BECN1	Beclin 1	29.6	20.6	30.2	76.2	77.5	85.7
NUP62 (p62)	Nucleoporin 62	12.4	5.1	21.2	50.0	47.3	52.5
LAMP1	Lysosomal-associated membrane protein 1	81.4	56.9	91.0	493.6	525.9	543.8
TFEB	Transcription Factor EB	12.7	5.3	20.6	25.0	20.5	21.1

Abbreviations: CNS, control non-smokers; CS, control smokers; COPD, chronic obstructive pulmonary disease.

**References**

1. Di Stefano A, Caramori G, Barczyk A, *et al.* Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD. *Thorax* 2014; 69: 516–524.
2. Chen S, Zhou Y, Chen Y, *et al.* Fastp: An ultra-fast all-in-one FASTQ preprocessor. *Bioinformatics* 2018; 34: i884–i890.
3. Sauler M, McDonough JE, Adams TS, *et al.* Characterization of the COPD alveolar niche using single-cell RNA sequencing. *Nat. Commun.* 2022; 13: 494.

For Review Only



Supplementary Figure 1

The figure depicts the expression levels of seven selected genes (BECN, CTSB, CTSD, LAMP1, MAP1LC3A, MAP1LC3B and TFEB) in different cell types (epithelial, endothelial, stromal and immune cells) of patients with COPD and control subjects obtained from the COPD Cell Atlas (<http://www.copdcellatlas.com/>). The expression level is represented by a colour-scale, whereas the fraction of the cells expressing the given gene is represented by the size of the dot.

31x60mm (1200 x 1200 DPI)